

**A BACTERIOLOGICAL STUDY ON  
*ARCANOBACTERIUM HAEMOLYTICUM*  
ISOLATED FROM HUMAN  
PHARYNGITIS IN AL-HILLA CITY**

**A Thesis**

**Submitted to the Council of the College of Medicine,  
University of Babylon, in Partial Fulfillments of the  
Requirements for the Degree of Master in Medical  
Microbiology**

**By**

*Rusul Uday Hashim*

**٢٠٠٦ A.D**

**١٤٢٧ A.H**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صَدَقَ اللَّهُ الْعَظِيمُ

سورة البقرة: الآية (٣٢)

We certify that this thesis was prepared under our supervision at the College of Medicine, University of Babylon, as a partial requirement for the Degree of Master in Medical Microbiology.

**Signature .....**

**Name: Mohammed Sabri**

**Assistant Professor of Microbiology**

**Supervisor**

In view of the available recommendation ,I forward this thesis for debate by the Examining Committee.

**Signature .....**

**Name: Mohammed Sabri**

**Assistant Professor of Microbiology**

**Head of Department of**

**Microbiology**

We, the examiner committee, certify that we have read the thesis entitled **(A bacteriological study on *Arcanobacterium haemolyticum* isolated from human pharyngitis in Al-Hilla City)** and have examined the student **(Rusul Uday Hashim)** in its contents, and that in our opinion it is accepted as a thesis for the degree of Master of Science in Medical Microbiology.

**Signature**  
**Assistant Prof.**  
**Dr. Safa Sahib Naji**  
**College of Medicine**  
**Babylon University**  
**(Chairman)**

**Signature**  
**Assistant Prof.**  
**Dr. Rahi kalaf Al-Yasiry**  
**College of Medicine**  
**Al-Quadisiya University**  
**(Member)**

**Signature**  
**Assistant Prof.**  
**Dr. Salman Aziz Addoos**  
**Department of Microbiology**  
**College of Medicine**  
**Al-Kufa University**  
**(Member)**

**Signature**  
**Assistant Prof.**  
**Dr. Muhammed Sabri A. Razzak**  
**Department of Microbiology**  
**College of Medicine**  
**Babylon University**  
**(Member and Supervisor)**

Approved for the College Committee of Graduate Studies.

**Signature**  
**Assistant Prof.**  
**Dr. Ali Khair Alla Al-Zubaidy**  
**Dean of College of Medicine**  
**Babylon University**

# *Dedication*

*To . . .*

*My Family*

## ***Acknowledgements***

I am deeply indebted to my supervisor, Assistant Professor Mohammed Sabri Abdul-Razzak, Ph.D., Head of Microbiology Department, College of Medicine, University of Babylon for his guidance, patience, and supervision. This thesis would not have been possible, without his sincere help and assistance.

My thanks are also due to all members of the Department of Microbiology for their generous co-operation.

***Rusul***

**A BACTERIOLOGICAL STUDY ON  
*ARCANOBACTERIUM HAEMOLYTICUM*  
ISOLATED FROM HUMAN  
PHARYNGITIS IN AL-HILLA CITY**

**ABSTRACT**

A Total ٣٠٠ throat swabs were obtained from patients of both sexes suffering from acute or chronic pharyngitis (children and adults) and admitted to Hilla Teaches Surgical Hospital . It was found that only eight isolates of *A.haemolyticum* were identified. Three of them were isolated from female and five from male patients whereas no isolates of *A.haemolyticum* were found in the healthy controls.

Colony morphology and type of hemolysis on blood agar divided *A.haemolyticum* isolates into smooth and rough colony type. In this study, smooth and rough colony types were seen on human blood agar after ٤٨hrs. of incubation. It was observed that three isolates were of the smooth type and five of the rough one.

Some virulence factors of bacteria were also studied, the results showed that all bacterial strains produced lipase and phospholipase D but not protease. The ability of the bacterial isolates to produce hemolysin was also investigated and it was found that only three isolates were able to produce hemolysin and these isolates were smooth type, whereas five isolates had no ability to produce hemolysin and they were of rough type. The results also showed that the strains were positive for reverse CAMP test which had capacity to block the hemolytic activity of the beta-lysine (phospholipase C) produced by *Staphylococcus aureus*.

The effect of temperature on the bacterial growth was also studied. It was found that *A. haemolyticum* could grow well at 20, 30, 35, 40°C as well as 4°C. This bacterial growth was inhibited completely at a temperature above 40°C. The same profile of temperature was seen on both smooth and rough isolates of *Arcanobacterium haemolyticum* under investigation.

The effect of some antibiotics on *A. haemolyticum* was investigated, the results showed that all isolates were sensitive (100%) to erythromycin, penicillin and azithromycin. On the contrary, all isolates were resistant (100%) to gentamycin whereas some isolates showed resistance in lesser degrees to vancomycin (72.5%) to cefotaxime (00%), and to cephalixin, clindamycin and ampicillin

(37%) . The isolates were also resistant to deoxycycline, ciproflaxine and tetracycline at a rate (20%).

## LIST OF CONTENTS

| Item No. | Subject                      | Page    |
|----------|------------------------------|---------|
|          | <i>Dedication</i>            |         |
|          | <i>Acknowledgements</i>      |         |
|          | <i>Abstract</i>              | I – II  |
|          | <i>List of Contents</i>      | III – V |
|          | <i>List of Tables</i>        | VI      |
|          | <i>List of Figures</i>       | VII     |
|          | <i>List of Abbreviations</i> | VII     |

## Chapter 1: Introduction and Literatures Review

|                 |  |             |
|-----------------|--|-------------|
| ۱.۱             | Introduction                               | ۱           |
| ۱.۲             | Literatures Review                         | ۳           |
| ۱.۲.۱           | General Features of <i>A.haemolyticum</i>  | ۳           |
| ۱.۲.۲           | Taxnomy of <i>A.haemolyticum</i>           | ۵           |
| ۱.۲.۳           | Pathphysiology of <i>A.haemolyticum</i>    | ۶           |
| ۱.۲.۴           | Epidemiology of <i>A.haemolyticum</i>      | ۹           |
| ۱.۲.۵           | Virulence Factors of <i>A.haemolyticum</i> | ۱۱          |
| ۱.۲.۵.۱         | Phospholipase D (PLD)                      | ۱۱          |
| ۱.۲.۵.۲         | Lipase                                     | ۱۴          |
| ۱.۲.۵.۳         | Deoxyribonuclease (DNase)                  | ۱۵          |
| ۱.۲.۵.۴         | Hemolysin                                  | ۱۶          |
| ۱.۲.۵.۵         | Neuraminidase                              | ۱۷          |
| ۱.۲.۶           | CAMP Test                                  | ۱۸          |
| <b>Item No.</b> | <b>Subject</b>                             | <b>Page</b> |
| ۱.۲.۷           | The CAMP Inhibition Test                   | ۱۸          |

|  |   |    |
|--|---|----|
| ۱.۲.۸                                    | Role of <i>A.haemolyticum</i> in pharyngitis          | ۲۰ |
| ۱.۲.۹                                    | Antimicrobial Susceptibility                          | ۲۲ |
| ۱.۲.۹.۱                                  | Penicillin VK   | ۲۴ |
| ۱.۲.۹.۲                                  | Erythromycin  | ۲۵ |
| <b>Chapter II: Materials and Methods</b> |   |    |
| ۲.۱                                      | Materials   | ۲۶ |
| ۲.۱.۱                                    | Laboratory Instruments                                | ۲۶ |
| ۲.۱.۲                                    | Chemical and Biological Materials                     | ۲۷ |
| ۲.۲                                      | Patients and Methods                                  | ۲۸ |
| ۲.۲.۱                                    | Patients  | ۲۸ |
| ۲.۲.۲                                    | Collection of specimens                               | ۲۸ |
| ۲.۲.۳                                    | Reagents  | ۲۹ |
| ۲.۲.۴                                    | The Preparation of Media                              | ۳۰ |
| ۲.۲.۵                                    | Biochemical Tests                                     | ۳۳ |
| ۲.۲.۶                                    | Isolation and Identification of <i>A.haemolyticum</i> | ۳۵ |
| ۲.۲.۷                                    | Virulence Factors Test                                | ۳۶ |
| ۲.۲.۷.۱                                  | Hemolysin Production                                  | ۳۶ |

|  |  |             |
|--|--|-------------|
| ۲.۲.۷.۲                                    | Lipase Production                                    | ۳۶          |
| ۲.۲.۷.۳                                    | Protease Production                                  | ۳۶          |
| ۲.۲.۷.۴                                    | Phospholipase D Production                           | ۳۷          |
| ۲.۲.۸                                      | Effect of incubation temperature on bacterial growth | ۳۷          |
| <b>Item No.</b>                            | <b>Subject</b>                                       | <b>Page</b> |
| ۲.۲.۹                                      | Antibiotic Sensitivity Test                          | ۳۸          |
| <b>Chapter III: Results and Discussion</b> |  |             |
| ۳.۱  | Isolation and Characterization                       | ۴۰          |
| ۳.۱.۱                                      | The Characteristics of <i>A. haemolyticum</i>        | ۴۴          |
| ۳.۱.۲                                      | Biotyping of <i>A. haemolyticum</i>                  | ۴۶          |
| ۳.۲  | Reverse CAMP Test                                    | ۴۸          |
| ۳.۳  | Virulence Factor of <i>A. haemolyticum</i>           | ۴۹          |
| ۳.۳.۱                                      | Hemolysin  | ۴۹          |
| ۳.۳.۲                                      | Protease   | ۵۰          |
| ۳.۳.۳                                      | Lipase   | ۵۱          |
| ۳.۳.۴                                      | Phospholipase D                                      | ۵۲          |

|  |  |    |
|--|--|----|
| ٣.٤  | Effect of Temperture on <i>A.haemolyticum</i> growth | ٥٤ |
| ٣.٥  | Effect of some antibiotics on <i>A.haemolyticum</i>  | ٥٥ |
| <b>Chapter IV: Conclusions and Recommendations</b> |  |    |
| ٤.١  | Conclusions  | ٦١ |
| ٤.٢  | Recommendation                                       | ٦٣ |
|  | <b>References</b>                                    | ٦٤ |
|  | <b>Abstract in Arabic</b>                            |    |

### LIST OF TABLES

| Table No. | <i>Title</i>                           | Page |
|-----------|--|------|
| ١         | Laboratory Instruments Used            | ٢٦   |
| ٢         | Chemical and Biological Materials Used | ٢٧   |

|   |   |    |
|---|---|----|
| ۳ | Frequency of Positive Culture and Negative Culture on Selective Media | ۴۲ |
| ۴ | Distribution of <i>A.haemolyticum</i> Infections Among Age and Sex    | ۴۳ |
| ۵ | Diagnostic Features of <i>A.haemolyticum</i>                          | ۴۵ |
| ۶ | Properties of the Two Biotype of <i>A.haemolyticum</i>                | ۴۷ |
| ۷ | Detection of Virulence Factors on the Growth of <i>A.haemolyticum</i> | ۵۴ |
| ۸ | Effect of Temperature on the Growth of <i>A.haemolyticum</i> Isolates | ۵۵ |
| ۹ | Effect of Antibiotics on the Growth of <i>A.haemolyticum</i>          | ۵۶ |

## LIST OF FIGURES

| Table No. | Title   | Page |
|-----------|---|------|
| ١         | <i>A.haemolyticum</i> Appearance on Blood Agar      | ٤٦   |
| ٢         | Phospholipase D Production by <i>A.haemolyticum</i> | ٥٣   |

## LIST OF ABBREVIATIONS

|       |                                      |
|-------|--------------------------------------|
| PLD   | Phospholipase D                      |
| CAMP  | Christie, Atkins, and Munch-Peterson |
| PC    | Phosphatidylcholine                  |
| PA    | Phosphatidic Acid                    |
| LPA   | Lipid mediator Lysophosphatidic Acid |
| TAG   | Triacylglycerol                      |
| DNase | Deoxyribonuclease                    |
| TSA   | Tryptic Soy Agar                     |
| TCA   | Trichloroacetic Acid                 |

# دراسة بكتريولوجية على

## *Arcanobacterium haemolyticum*

### المعزولة من حالات التهاب البلعوم في مدينة الحلة

#### الخلاصة

من بين مجموع ٣٠٠ مسحة بلعمية تم جمعها من المركز الاستشاري لمستشفى الحلة الجراحي استحصلت من المرضى الذين يعانون من التهاب البلعوم ( الحاد أو المزمن ) ومن كلا الجنسين, تم عزل وتشخيص ثمان عزلات من بكتريا *Arcanobacterium haemolyticum* : ثلاث عزلت من الإناث وخمس من الذكور . في حين لم يتم عزل البكتريا من الأشخاص غير المصابين .

أظهرت النتائج اعتماداً على قابلية البكتريا على إنتاج إنزيم الهيمولايسين والصفات المظهرية للمستعمرة على تقسيم البكتريا إلى النوع الخشن والنوع الناعم على أكار الدم المغذي ، إذ لوحظ وجود ثلاث عزلات من النوع الناعم وخمس عزلات من النوع الخشن .

درست بعض عوامل الضراوة لهذه البكتريا ، وقد وجد أن جميع العزلات موجبة لإنتاج إنزيم اللايبيز والفسفولايبيز D ، في حين لم تظهر العزلات قابلية على إنتاج البروتيز .

كما درست قابلية البكتريا على إنتاج إنزيم الهيمولايسين من النوع  $\beta$  ، إذ وجدت ثلاث عزلات فقط لها القابلية على إنتاج الهيمولايسين حيث إن هذه العزلات من النوع الناعم ، في حين لم تظهر العزلات الباقية قابلية لإنتاج الهيمولايسين والتي تعود إلى النوع الخشن .

وقد أظهرت النتائج أن جميع العزلات موجبة لفحص CAMP العكسي حيث وجد لها القابلية على تثبيط الفعالية التحليلية لإنزيم  $\beta$ -lysin المنتج من قبل بكتريا *Staphylococcus aureus* .

وتم أيضاً دراسة تأثير الحرارة على نمو البكتريا ، وقد لوحظ بأن البكتريا تنمو عند درجات الحرارة ( ٤ - ٤٠ ) م° ، كما أن الحرارة فوق ( ٤٠ م° ) تثبط النمو البكتيري بشكل كامل. وقد لوحظ أيضاً إن التأثير الحراري كان مماثلاً على العزلات الناعمة والخشنة من بكتريا *Arcanobacterium haemolyticum* .

درس تأثير بعض المضادات الحياتية على عزلات بكتريا *A.haemolyticum* وأظهرت النتائج بان جميع العزلات حساسة لكل من الارثرومايسين والبنسلين والازوثرومايسين في حين على العكس لوحظ بان جميع العزلات مقاومة وبشكل كامل للجنتامايسين وبدرجة اقل لكل من الفانكوميسين ( ٦٢.٥ % ) إضافة إلى الكلندامايسين والامبسلين ( ٣٧ % ) ، وأيضاً للدوكسيساكيلين وسبروفلاكسين والتتراساكيلين ( ٢٥ % ) .

دراسة بكتريولوجية على

## *Arcanobacterium haemolyticum*

المعزولة من حالات التهاب البلعوم في مدينة  
الحلة

رسالة

مقدمة إلى مجلس كلية الطب في جامعة بابل كجزء من  
متطلبات نيل

درجة الماجستير في علم الأحياء المجهرية الطبية  
من قبل

# رسل عدي هاشم

بكالوريوس علوم ( الأحياء المجهرية )

٢٠٠٦ م

١٤٢٧ هـ

# **Chapter One**

## **Introduction and Literature Review**

### **1.1 Introductions**

*Arcanobacterium haemolyticum* (formerly *Corynebacterium haemolyticum*) is an aerobic gram positive rod first found in 1946 in persons with pharyngitis and skin infections (Maclean, 1946).

*A. haemolyticum* has been implicated as an important cause of pharyngitis in adolescents and young adults, frequently causing an exanthema that may mimic viral exanthema, toxic erythema or drug eruption which usually resolve in few days with or without therapy (Gaston, 1996).

Serious infections such as brain abscess, meningitis, septicemia, endocarditic and osteomyelitis occur less frequently but are fatal if not treated early (Hoosen, *et.al.* 1990); other less serious infections include chronic skin ulcers, cellulites and otitis media (Bhat, *et.al.*, 1997).

The taxonomical position of *A. haemolyticum* has caused confusion in the past, largely because of its close phenotypical similarity to *Actinomyces pyogenes* (formerly *Corynebacterium*

*pyogenes*), which is primarily an animal pathogen (Coyle and Lipsky, ۱۹۹۰).

Antibiotic susceptibility tested on human blood agar have shown that *A.haemolyticum* is susceptible to many types of antibiotics however, some strains show resistance to certain antibiotics (Biswas, *et.al.*, ۲۰۰۳) .

Infections is most common in ۱۰-۲۰ years old persons, and is thought to result from droplet transfer from infected persons (Gaston and Zurowski, ۱۹۹۶).

The demonstration that *A. haemolyticum* is not a component of the human commensal flora is essential to establishing its role in human infection (Mackenzie, *et. al.*, ۱۹۹۰).

There is no independent study on this bacterium conducted in Iraq, so this study is aimed to:

۱. Isolation and characterization the bacteria associated with pharyngitis from patients (children and adults) from both sexes.
۲. Study the effect of some antibiotics on *A.haemolyticum* isolates.
۳. Study some factors associated with the pathogenicity of *A.haemolyticum* such as lipase, protease, and phospholipase D.
۴. Investigate the effect of temperature on the activity and survival of this bacterium.

## 1.2 Literature Reviews

### 1.2.1 General Features of *A. haemolyticum*

*A. haemolyticum* is a pleomorphic, gram positive rod, facultatively anaerobic, non motile and non sporulating. It can sometimes appear granular or beaded and resemble irregular cocci. The growth is enhanced by the addition of 0-10% CO<sub>2</sub> (Clarridge, 1989).

Optimal growth is obtained utilizing blood or serum enriched media incubated at 37°C. The colony size and degree of hemolysis vary with the type of blood cell (Cummings, *et.al.*, 1993).

Colonies on human blood agar after 24 hour incubation are of 0.5mm diameter, and exhibit a narrow zone of hemolysis; at 48 hours, the colony diameter is 1mm with hemolysis zone of 3.0mm (Cummings, *et.al.*, 1993).

On sheep or human blood agar, overnight colonies are tiny and little or no hemolysis is observed; at 48-72 hours, the haemolysis zone is about 1mm in diameter. Colonies are circular, discoid, opaque and whitish. A uniform feature of *A. haemolyticum* colonies is a black opaque dot at the center of colony which remains if the colony is scraped aside (Waagner, 1991). The colonies of *A. haemolyticum* have been suspected on the basis of the growing

time interval ( $\xi^{\wedge}$ ), reduced size (diameter less than 1 mm), the presence of a narrow zone of incomplete beta- haemolysis and the typical pitting of the culture medium beneath the colony. The definitive identification is realized on the basis of the microscopical appearance (diphtheroid gram- positive bacilli), negative catalase test and inverse CAMP test (Coman, *et.al.*, 1996). *A.haemolyticum* does not produce catalase or indole. The bacterium does not hydrolyze esculine, gelatin and urea. Most strains do not reduce nitrate. *A.haemolyticum* produce acid from glucose, lactose and maltose, gives no hemolysis in CAMP test (reverse CAMP positive) and produces lipase, extracellular deoxyribonuclease (DNase) and phospholipase D (Krech and Hollis, 1991).

The peptidoglycan of *A. haemolyticum* contains lysine as the dibasic amino acid, glutamic acid and alanine are detected in the hydrolysates (Collins, *et.al.*, 1982).

Colony morphology ,beta- hemolysis on sheep or human blood agar and the ability to ferment sucrose or trehalose defined two biotypes of *A.haemolyticum* : one which is the smooth type, grow as smooth, beta-hemolytic colony and fermented sucrose, whereas the other, the rough type ,grows as a rough colony and is non hemolytic and negative for sucrose and trehalose fermentation (Carlson, *et.al.*, 1994). Both biotypes have extracellular amorphous polymeric

materials containing at least proteins. None of the strains possess a paracrystalline S (surface) layer (Lounatmaa, *et.al.*, 1993).

The smooth type is predominant in wound infections, whereas the rough type is isolated almost exclusively from respiratory tract specimens (Fell, *et.al.*, 1977).

*A.haemolyticum* is accepted as an occasional human pathogen causing pharyngitis, some times associated with cervical adenitis and often with scarlatiniform rash. *A.haemolyticum* has also been isolated from chronic skin ulcers and occasionally from other lesions such as brain abscess and osteomyelitis (Collee, *et.al.*, 1996).

*A.haemolyticum* closely resembles *Actinomyces pyogenes* that is also gram-positive, catalase negative and produces beta-hemolytic colonies, however, the two organisms are easily differentiated as *Actinomyces pyogenes* hydrolyses gelatine rapidly, and produce acid from xylose (Goyal, *et.al.*, 2000).

### 1.2.2 Taxonomy of *A. haemolyticum*

Initially named *Corynebacterium haemolyticum*, the bacterium now termed as *Arcanobacterium haemolyticum*, was first described in 1940 as the pathogenic agent causing pharyngitis and cutaneous infections among US servicemen (Macleod, 1946). As a result of its close resemblance to *Corynebacterium pyogenes*, some investigators

have believed the bacterium to be mutant of this species and appended a subspecies name, *Corynebacterium pyogenes* sub sp. hominis (Collins, *et.al.*, 1982).

The factors that have contributed to the earlier confusion surrounding the taxonomy of *A. haemolyticum* are the following:

1. Designation of the organism as *corynebacterium pyogenes* var. hominis by some investigators (Soucek and Souckov, 1964).
2. A report that it is mutant of *Corynebacterium pyogenes* (Barksdale, *et.al.*, 1907).
3. The description of positive catalase test that is not observed by conventional methods (Barksdale, *et.al.*, 1907).
4. The lack of hemolysis after 24 hour incubation on sheep or human blood agar.

On the basis of biochemical tests and peptidoglycan, cell wall fatty acid and DNA data, *A. haemolyticum* have been removed from the genus *Corynebacterium*. It has been assigned to a new genus, *Arcanobacterium* (Latin "arcanus" = secretive), composed of this single species (Collins, *et.al.*, 1982).

### 1.2.3 Pathophysiology of *A. haemolyticum*

*A. haemolyticum* has been implicated as an important cause of pharyngitis in adolescents and young adults, frequently causing an

exanthema that may mimic a viral exanthema, toxic erythema or drug eruption which usually resolves in a few days with or without therapy (Gaston and Zurowski, 1996).

*A. haemolyticum* is an obligate pathogen, rarely isolated outside of the disease process. This organism causes pharyngitis and skin infections in human, although it can invade from the initial site of infection to cause meningitis, septic arthritis and endocarditis (Jost, *et.al.*, 2001).

*A. haemolyticum* may cause peritonsillar and pharyngeal abscesses (White and Foshee, 2000) subperiosteal abscess, sinusitis (Ford, *et.al.*, 1990), empyema with mycoplasma pneumoniae infections (Stacey and Bradlow, 1999), respiratory tract infections (Katkar, *et.al.*, 2000), central nervous system infections, paravertebral abscess as a complication of ingrown toenail (Dieleman, *et.al.*, 1989). Severe systemic infections such as endocarditis and meningitis have also been reported in immunocompromised patients (Minarik, *et.al.*, 1997). Recently, Biswas, *et.al.*, (2003) have reported a case of chronic osteomyelitis due to *A. haemolyticum*. Pyothorax in an immunocompetent adolescent patient have been reported (Parija, *et.al.*, 2000).

The first case of septic arthritis caused by *A. haemolyticum* has also been reported. The awareness of the pathogenic potential of this

organism has been increases in bone and joint infections (Goyal, *et.al.*, २०००).

*A.haemolyticum* has been described as an unusual pathogen causing pharyngotonsillitis and extrapharyngeal infections like ulcerative lesion infections mainly in patients with underlying conditions (peripheral vascular disease, diabetes, alcoholism) Panzara and Taranu, (२००१). There are increasing reports of systemic infections caused by *A.haemolyticum* (Parija, *et.al.*, २०००). Rarely is a patient with pharyngitis caused by *A.haemolyticum* hospitalized because of an inability to swallow. No deaths have been reported resulting from pharyngitis caused by *A.haemolyticum*, although *A.haemolyticum* have caused the death of two patients with endocarditis Chandrasekar and Molinari,( १९८४).

*A.haemolyticum* also appears to be isolated from both immunocompetent and immunocompromised hosts (Alos, *et.al.*, १९९०).

*A. haemolyticum* has rarely been reported in animals and its pathogenicity in animals has not been well documented (Robert, १९६९). This organism has not been identified as a part of the normal microflora of animals (Waagner, १९९१). The role of *A.haemolyticum* as a zoonotic disease and its differentiation from the closely related animal pathogen *A.pyogenes* need to be defined (Billington, *et.al.*, २००२).

Humans are believed to be its main environmental reservoir (Alonso, *et.al.*, 2002) although, usually, *A. haemolyticum* is not a respiratory colonizer.

*A. haemolyticum* has been isolated from pus drained from ankle joint, probably due to the spread of infections from abrasion over medial malleolus (Ford, *et.al.*, 1990). Skin rash and predominant growth on multiple blood cultures suggest a causative role for *Arcanobacterium haemolyticum*.

Throat infections are often accompanied by cervical lymphadenopathy (Mackenzie, *et.al.*, 1990). An erythematous morbilliform or scarlatinal rash of the trunk, neck, or extremities is associated with 20% to 50% of cases (Banck and Nyman, 1986).

The mechanism responsible for adherence of *A. haemolyticum* to the pharyngeal mucosa is unknown (Karpathios, *et.al.*, 1992). The pathophysiology of the rash is also unknown, However, the hypothesis that the rash is caused by bacterial exotoxin is reasonable.

Although initial attempts to identify toxins unproductive, phospholipase D (PLD), neuraminidase and hemolysin have been subsequently identified as extracellular toxin secreted by *A. haemolyticum* (Soucek and Souckov, 1974).

Phospholipase D is known to bring about tissue damage, as elaborated by this organism as well as by the closely related bacterium, *Corynebacterium pseudotuberculosis*, an important pathogen of sheep (Linder, 1997). Phospholipase D shares many properties with Corynebacterial PLDs, including biochemical and biological activities is responsible for the toxicity of the venom of the brown recluse spider (Bernheimer, *et.al.*, 1980).

#### 1.2.4 Epidemiology of *A.haemolyticum*

*A.haemolyticum* infections is often reported from deliberate screening for the organism of a large number of patients with sore throat. Most cases involve pharyngitis or tonsillitis and approximately 0.1% are exudative (Miller, *et.al.*, 1986).

*A.haemolyticum* occurs only after recurrent infections, which are thought to be related to incorrect initial diagnosis, resulting in less-than-optimum treatment (Banck and Nyman, 1986).

**Infections is most common in 10-20 years old persons, and is thought to result from droplet transfer from infected persons (Gaston and Zurowski, 1996). Symptoms resemble those of beta- hemolytic Streptococci or viral infections. The spectrum of disease ranges from sore throat to, in rare cases, a life- threatening membranous**

**pharyngitis resembling diphtheria (Green and Lapeter, 1981).**

The demonstration that *A.haemolyticum* is not a component of the human commensal flora is essential in establishing its role in human infection (Mackenzie, *et.al.*, 1990). Epidemiologic contact studies indicate that the infection likely spreads through an unknown route by human contact with people who are infected (Miller, *et.al.*, 1986).

*A.haemolyticum* has rarely been recovered in healthy individuals (0.02%), indicating the probable absence of a chronic carrier state, although direct inoculation studies indicate that transient asymptomatic colonization by *A.haemolyticum* can occur (Karpathios, *et.al.*, 1992). *A.haemolyticum* most frequently causes opportunistic infection in immunocompromised patients.

*A.haemolyticum* occurs relatively often in polymicrobial infections together with typical respiratory pathogens such as *Streptococci* (Linder, 1997). It is not yet determined if the presence of other microorganism contributes a synergistic role in the pathogenicity of *A.haemolyticum* (Skov, *et.al.*, 1998).

Less frequent infection including osteomyelitis, meningitis and brain abscess can occur due to this bacteria (Funke, *et.al.*, 1997).

*A.haemolyticum* has rarely been reported in animals and its pathogenicity in animals has not been well documented (Richardson

and Smithpj, 1968). It is important to acknowledge the fact that this organism's presence is increases because some of the infections may become serious (Mehta, 2003).

Some 0.5% to 3% of cases of pharyngitis can be traced of *A.haemolyticum* depending on the population studied with the highest number among 10-30 years-old-patients. (Banck and Nyman, 1986).

### **1.2.5 Virulence factors of *A.haemolyticum***

*A.haemolyticum* is known to produce un characterized hemolytic agents (Gaston and Zurowski, 1996) and two biochemically defined extracellular products; a neuraminidase and phospholipase D acting preferentially on sphingomyelin and generating ceramide phosphate in the target membrane (Souck, *et.al.*, 1971).

#### **1.2.5.1 Phospholipase D (PLD)**

Phospholipase D activity was first discovered in carrot extracts as a phospholipids- specific phosphodiesterase activity that hydrolyzed phosphatidylcholine to yield phosphatidic acid (PA) and choline (Hanahan and Chaikoff 1947).

Over 20 years of biochemical studies culminating in the identification of PLD genes in the mid 1990s have implicated PLD activity and its product PA in wide range of physiological processes and disease, including inflammation, diabetes (Hammond, *et.al.*, 1990), cytoskeletal rearrangement (Cross, *et.al.*, 1996), vesicle trafficking and exocytosis (Siddhanta, *et.al.* 2000), phagocytosis (Kusner, *et.al.*, 1996), neuronal and cardiac stimulation (Park, *et.al.*, 2000), matrix metalloproteinase production (Reich, *et.al.*, 1990), oncogenesis, (Welsh, *et.al.*, 1994), and the oxidative respiratory burst in neutrophils (Waite, *et.al.*, 1998). In addition, exogenously added phosphatidic acid (PA) and PLD stimulate DNA synthesis in cells, indicating a potential role for PLD in mitogenesis (Exton, 1994).

PLD activity appears to be present in most cell types (Meier, *et.al.*, 1999), with the reported suggested exceptions of peripheral leukocytes and some lymphocyte lines (Bradshaw, *et.al.*, 1996).

PLD activities have been reported within the plasma membrane, cytosol, endoplasmic reticulum, Golgi and nuclei (Provost, *et.al.*, 1996). The PLD gene from *A.haemolyticum* has been cloned and shown to have a high degree of homology with that of *C.pseudotuberculosis*, which it is thought to participate in vascular permeability and dissemination of the pathogen. (Cuevas and Songer, 1993).

The activation of PLD in response to variety of hormones, growth factor and neurotransmitters catalyzes the hydrolysis of phosphatidylcholine (PC), generating choline and phosphatidic acid (Billah and Anthes, 1990). Phosphatidic acid generally recognized as the signaling product of PLD functions as an effector in multiple physiological processes (Kim, *et.al.*, 2003).

PLD activity is present in a wide variety of cell types including blood platelets, fibroblasts, muscle cells and others (Kanfer, *et.al.*, 1996).

PLD activity has been implicated in the regulation of cell growth (Ramires de Molina, *et.al.*, 2001), membrane traffic and action dynamics (Cockcroft, 2001), metastasis (Paii, *et.al.*, 1994), the burst of neutrofiles (Suchard, *et.al.*, 1994) and specific signaling pathways (Liscovitch and Amsterdam, 1989).

PLD enzymes is local inflammation by catalyzing the production of the lipid mediator lysophosphatidic acid (LPA) (Van Dijk, *et.al.*, 1998).

PLD is known to bring about tissue damage as elaborated by *A.haemolyticum* as well as the closely related bacterium, *C.pseudotuberculosis* an important pathogen of sheep ( Linder, 1997).

The enzyme was responsible for the dermonecrotic, as well as the synergistic hemolytic activity of the organism that elaborate it (Soucek, *et.al.*, 1971). The role of potentiated cytotoxicity caused by the combined activity of PLD and cooperative agents such as

cholesterol data involving phagocytosis (Linder and Bernheimer, 1982).

PLD has been found to be markedly elevated in various cancer tissues (Uchida, *et.al.*, 1999 and Zhao, *et.al.*, 2000), multidrug resistant cancer cells (Fiucci, *et.al.*, 2000) and transformed cell (Frankel, *et.al.*, 1999). Demonstration of PLD production by the reverse CAMP test is useful in the identification of *A.haemolyticum* (Jurankova and Votava, 2001).

Soucek, *et.al.*, (1962) have reported that a substance in culture supernatant fluids inhibites the lytic action of beta-toxin of *Staphylococcus aureus*, and the description of the active substances in culture supernatant fluids is expanded to include three elements:

An ( $\alpha$ ) component possessed lecithinase activity, dermonecrotic activity and beta-hemolysin inhibiting activity, adsorbed to erythrocytes, and dissolved egg yolk (Soucek and Souckova, 1966).

On the other hand ( $\beta$ ) component lysed erythrocytes and ( $\gamma$ ) component possessed lipase activity, possibly corresponding to phospholipase A activity.

### 1.2.5.2 Lipase

Lipases are enzymes that catalyze hydrolysis of fatty acid ester bond in triacylglycerol (TAG) thus releasing free fatty acid (note the reaction is reversible), So the enzyme can catalyze esterification of glycerol to form mono, di and triglyceride (Shalita, *et.al.*, 1982).

Lipases have been reported to be large molecules of aggregates of protein- lipid or protein- protein (Pablo, *et.al.*, 1974). Most lipases have optimum temperature ranging from 30-40°C, but it should be recognized that while most enzymes stop catalysis at 0°C because liquid substrates become solid ice.

Many lipases are produced constitutively, although their production may be influenced by the nutritional and physical condition of the culture (Kurioka and Matsuda, 1975).

The physical role of extracellular lipase is probably nutritional; some may hydrolyze exogenous triglycerides to provide free fatty acids for use as an energy source (Lonon, *et.al.*, 1988).

Lipase are important catabolic enzymes in phospholipid metabolism; the mechanism of their action in infectious process is not well understood (Dennis, 1983).

Lipase may help spread the microorganism in cutaneous and subcutaneous tissues (Koneman, *et.al.*, 1992). Lipase that may be hydrolyzing lipid on epithelial surface of humans enhances the colonization of the skin (Willet, 1976). The enhancement of growth by lipids by *Arcanobacterium* has been used as an aid to identification (Coyle, *et.al.*, 1990).

### 1.2.5.3 Deoxyribonuclease (DNase)

DNase is an extracellular endonuclease (Harper, *et.al.*, 1977), that is specific for hydrolysis (degradation) of DNA . The physical and chemical properties of DNA differ from those of oligonucleotides or mononucleotides and these differences are used to detect hydrolysis of DNA by DNase (Blazevic and Edever, 1970).

DNases are extracellular products that may serve to facilitate the liquification of pus and spreading of bacteria through tissue planes (Mandell, *et.al.*, 2000).

The *Arcanobacterium* DNase degrades host nucleic acid, making nucleotide available as nutrients (Jost and Billington, 2000).

The DNase of *Arcanobacterium* may aid in the depolymerization of highly viscous DNA released from disintegrating host cells in inflammatory lesions (Ramos, *et.al.*, 1997).

#### 1.2.5.4 Hemolysin

Hemolysin (bacterial) is a soluble substance elaborated by bacteria, that dissolves or breaks up red blood cell with consequent liberation of hemoglobin (Macfaddin, 2000). *A.haemolyticum* is considered to be beta- hemolytic, that hemolysis is far more subtle than what is seen with group A *Streptococcus* and can require 48-72 hours for detection (Cummings, *et.al.*, 1993).

Colonies on sheep or human blood agar are circular discoid, opaque and whitish. Detection is clearly influenced by the choice of media and atmosphere of incubation (Cummings, *et.al.*, 1993), both colony size and zone of hemolysis are significantly greater on tryptic soy agar (TSA) media. The CO<sub>2</sub> atmosphere is clearly superior for the production of larger hemolytic zones. Anaerobic incubation produces the smallest colonies and zone of hemolysis. Since the production of noticeable hemolysis is critical for the recognition of *A.haemolyticum* colonies in the presence of other flora (Cumming, *et.al.*, 1993).

Trypticase soy agar is a superior media and CO<sub>2</sub> is a superior atmosphere for beta- hemolysis. The detection of hemolysis by *A.haemolyticum* can be facilitated by using special double – layered human blood agar plates (Bank and Nyman, 1989).

### 1.2.5.5 Neuraminidase

Neuraminidase is a potential toxin produced by *A.haemolyticum* (Muller, 1973). Neuraminidase is a virulence factor, especially in bacteria that inhabit mucosal surfaces (Taylor, 1996), and they may play several roles in virulence.

Neuraminidase (N- acetylneuraminyl hydrolase) removes sialic acid from glycolipid, glycoproteins, and poly- and oligosaccharides (Roggentin, *et.al.*, 1989). This enzyme can make sialic acid a viable as a carbon source to promote growth in nutrient-limited environment (Byers, *et.al.*, 1997). The action of neuraminidase can decrease mucous viscosity (Gottschalk, 1960), possibly enhancing the colonization of the underlying tissues. The *Arcanobacterium* neuraminidases are probably required for the colonization of the host and some (early) pathogenic processes, but may not be required in the latter stages of infections (Jost and Billington, 2000). This enzyme is required for nasopharyngeal colonization and subsequent transition to the lower respiratory tract, but it is not required for lung infection (Orihuela, *et.al.*, 2004). Neuraminidase can increase the susceptibility of mucosal IgA to bacterial protease (Reinholdt, *et.al.*, 1990).

Neuraminidase can enhance bacterial adhesion and colonization (Child and Gibbons, 1990) as well as susceptibility of the host to the

action of toxins (Galen, *et.al.*, 1992) by exposing cryptic host cell receptor molecules.

### 1.2.6 CAMP Test

This test is used to determine an organism's ability to produce and elaborate the CAMP factor which acts synergistically with Staphylococcal beta-hemolysin (beta-lysine) on sheep erythrocytes to produce alytic phenomenon (Darling, 1970). The CAMP factor is a thermo stable (heat-stable), extracellular (Christie, *et.al.*, 1944), diffusible protein product of group B Streptococci (Brown, *et.al.*, 1974), which lysis ruminant erythrocyte treated with beta-hemolysin (Jokipit and Jokipii, 1976). It manifests specific synergism with sphingomyelinase C (Gubash, 1978) on sheep blood. CAMP factor might interfere with precipitation of ceramide in situ; removal of ceramide would leave wide spaces in outer layer, rendering the inner layer in sheep cells susceptible to pressure from inside the cell and possible enzymatic attack or enough open areas in the outer layer of sheep to expose the inner layer to action of a broader-spectrum phospholipase C (Gubash, 1978).

### 1.2.7 The CAMP Inhibition Test

CAMP inhibition (complete inhibition of the effect of *S.aureus* beta- hemolysin on sheep erythrocytes) is achieved by streaking the presumed *A.haemolyticum* strain at a right angle toward *S.aureus* and incubation overnight; beta- hemolysin inhibition zone in the form of triangle is observed, as in the case for *A. haemolyticum* (Patrick, *et.al.*, १००३).

The basis of the test is that *Staphylococcus aureus* and hemolysin act on the sphingomyelins in the cell membrane of sheep erythrocyte.

Beta-lysin of *Staphylococcus aureus* possesses phospholipase C (sphingomyelinase) activity (hemolysis, lysis) against sheep erythrocytes and hydrolyzes the sphingomyelin provided by the erythrocytes (Maheswaran and Lindorfer, १९६१).

Sphingomyelin (sphingolipids) is a class of lipids concerned with structure and function of cell membranes by providing barriers to indiscriminate exchange of compounds with extracellular fluids (Harrow and Mazur, १९६६).

Sphingomyelinase (sphingomyelin choline phosphohydrolase) from *Staphylococcus aureus* can attack the outer membrane of intact erythrocytes and produce water-insoluble ceramide and phosphorylcholine (Zwavall, *et.al.*, १९७३). PLD hydrolyzes sphingomyelins to N-acylsphingosylphosphates (Souckov and Soucek,

1974). *A. haemolyticum* phospholipase D (PLD) hydrolyzes these sphingomyelins, thus protecting the blood cell from haemolysis (Souckov and Soucek, 1972).

### 1.2.8 Role of *A. haemolyticum* in pharyngitis

Pharyngitis, called sore throat, is the inflammation of the pharynx (throat). Acute bacterial pharyngitis is most often caused by haemolytic Streptococci; however, in acute pharyngitis of adolescents and young adult, *A. haemolyticum* can be isolated from about 2% of the throat specimens (Bank and Nyman, 1986). This organism has been reported to be associated with pharyngitis and systemic infections in immunocompetent adolescents and young adults (Alberto, 2003). *A. haemolyticum* has been increasingly identified as a cause of exudative pharyngitis, clinically similar to that caused by beta-hemolytic streptococci (Karpathios, *et.al.*, 1992).

Characteristically, the infections has been recognized in children, adolescents, and young adults and is associated with a diffuse, some times pruritic, erythematous maculopapular skin rash on the extremities and trunk. Cases of *A. haemolyticum* infections with membranous pharyngitis that mimics diphtheria (Green and Lapeter, 1981) and with peritonsillar abcess have also been reported (Kovatch, *et.al.*, 1983).

The clinical picture of *A.haemolyticum* pharyngitis is indistinguishable from that of Streptococcal pharyngitis (Waagner, 1991). Sore throat and pharyngeal erythema are always present.

Additional symptoms and signs include fever, non productive cough, skin rash, and tonsillar exudates. The exudates are gray or white and usually patchy in distribution, although they are sometimes confluent (Miller, *et.al.*, 1986).

Lymphadenopathy is seen in 20-70% of the cases (Karpathios, *et.al.*, 1992). Although the posterior aspect of the pharynx has a similar appearance to that in scarlet fever, associated hemorrhagic macules on the palate or findings on the tongue are not present (Miller, *et.al.*, 1986).

The cutaneous manifestations appear unique to pharyngeal infections and have not been described in association with *A.haemolyticum* infections of other sites (Fell, *et. al.*, 1977).

Sometimes skin rash has been the predominant symptom. The rash has been described only in patients with pharyngitis and not in patients with infections of other sites. The exanthema usually develops 1-2 days after the pharyngitis, although occasionally, it is the initial manifestation of the infections. (Banck and Nyman, 1986)

The rash is most prominent on extensor surfaces of the extremities but may extend centripetally to the chest and back.

Erythema multiform and urticarial rash have been described in patients with *A.haemolyticum* pharyngitis (Miller, *et.al.*, 1986).

### 1.2.9 Antimicrobial Susceptibility

The antimicrobial susceptibility of *A.haemolyticum* in vitro has been tested in only a few studies (Carlson, *et.al.*, 1994). The organisms are usually susceptible to penicillin, and no strains resistant to erythromycin have been reported. *A.haemolyticum* has been reported to be uniformly susceptible to clindamycin, chloramphenicol, cephalosporins (Barker, *et.al.*, 1992). Tetracyclines and aminoglycosides appear effective in vitro, although occasional resistant strains have been encountered (Worthington, *et.al.*, 1980).

Tetracyclines are bacteriostatic, causing decrease in the effectiveness of penicillins when administered concurrently. Tetracycline acts by interfering with protein synthesis by binding to bacterial ribosome (Andrews, 1990). This antibiotic is bacteriostatic especially in large doses. In smaller doses, oral antibiotics do not reduce the number of organisms but they affect their functions.

The antibiotics can also inhibit various enzyme activities (Webster, *et.al.*, 1982), and modulate chemotactic, lymphocyte function and proinflammatory cytokines (Eady, *et.al.*, 1993). Tetracycline acts against susceptible microorganisms by inhibiting protein synthesis.

They enter bacteria by an energy- dependent process and bind reversibly to the 30 S ribosomal subunits of the bacteria (Chopra and Roberts, 2001). More often, resistance has been reported to sulphonamides,-trimethoprim (Ritter, *et.al.*, 1993)

Although clinical *A.haemolyticum* isolates have been reported to be susceptible to vancomycin (Wickremesinghe, 1981), a few faecal isolates of *A.haemolyticum* are resistant and harbour the transferable vancomycin resistance gene Van A (French, *et.al.*, 1992).

The susceptibilities of *A.haemolyticum* strains to cephalosporin, clindamycin, azithromycin and ciprofloxacin have not been reported before. But in a previous report all *A.haemolyticum* strains are susceptible to erythromycin (Bank and Nyman, 1986).

No significant differences have been noted in the antimicrobial susceptibility between pharyngeal and extrapharyngeal clinical *A.haemolyticum* isolates (Waagner, 1991).

Macrolides also exhibit excellent activities against *Arcanobacterium* and are an alternative to B-lactam antibiotic for the treatment of infection, since treatment failures due to B-lactam antibiotic to act intracellular have been reported (Patrick, *et.al.*, 2003).

Reports of treatment failure with penicillin in spite of low minimum inhibitory concentrations have been attributed to

tolerance and to failure to penetrate the intracellular location of the pathogen. In most cases, large doses of intravenous penicillin G have been effective (Waller, *et.al.*, 1991).

There are only a few reports of the susceptibility of *A.haemolyticum* to antimicrobial agents and only the penicillin and erythromycin have been reported (Nyman, *et.al.*, 1990).

#### 1.2.9.1 Penicillin VK

Oral penicillin has been studied and has been effective for treating pharyngitis, although some treatment failures have been reported (Karpathios, 1992). The ability of *A.haemolyticum* to invade HEP-2 cells and survive intracellular is investigated and has proved able to survive intracellular for 4 day thus creating intracellular reservoir of bacteria (Osterlund, 1990). Although most of isolated strains are susceptible to penicillin, erythromycin, clindamycin and tetracycline, high doses of penicillin, with or without gentamycin, is recommended for the treatment of deep infections (Alonso, *et.al.*, 2002). In patients with bacteremia, strains have been found to be resistant to penicillin, but clinical impact is unknown ( Nyman, *et.al.*, 1990).

The bactericidal activity of the penicillins is often related to their ability to trigger membrane associated autolytic enzymes that destroy the cell wall. This ability to inhibit bacterial cell wall

enzymes such as the transpeptidases usually confers on the penicillins bactericidal activity against gram- positive bacteria (Waxman and Strominger, 1983). Penicillin inhibits biosynthesis of cell wall mucopeptide, which is bactericidal against sensitive organism when adequate concentration are reached and most effective during stage of active multiplication (Snow, *et.al.*, 2001).

Reported successful treatment for systemic infections using a high dose of penicillin given intravenously erythromycin or penicillin in combination with aminoglycoside (Skov, *et.al.*, 1998).

#### 1.2.9.2 Erythromycin

Erythromycin has been proposed as the drug of choice, with parenteral antimicrobial drugs used for serious infections (Gaston and Zurowski, 1996).

*A.haemolyticum* seems to be uniformly susceptible to erythromycin in vitro. Erythromycin has been effective in oral doses of 200 mg four times daily for seven days (Miller, *et.al.*, 1986).

In children, age, weight and severity of infection determine proper dosage for more sever infections, dose is doubled. The strains is susceptible to erythromycin, ampicillin, vancomycin, clindamycin, rifampicin and penicillin. Erythromycin has been proposed as first-line therapy (Notario, *et.al.*, 2001).

Erythromycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl t RNA from ribosomes, arresting RNA-dependent protein synthesis (Miller, *et.al.*, 1986).

Erythromycin has been effective and most strains are susceptible to this antibiotic.

## Chapter Two

### **Materials and Methods**

#### **2.1 Materials**

##### **2.1.1 Laboratory Instruments**

Table (1): Laboratory Instruments Used

| No. | Instruments                         | Company           |
|-----|-------------------------------------|-------------------|
| 1   | <b>Sensitive Electronic Balance</b> | A and D, Japan.   |
| 2   | Autoclave                           | Stermite, Japan.  |
| 3   | Incubator                           | Memmert, Germany. |
| 4   | Distillator                         | GFL- Germany.     |
| 5   | Centrifuge                          | Hermle, Japan.    |
| 6   | Oven                                | Memmert, Germany. |
| 7   | Refrigerator                        | Concord, Italy.   |

|    |                  |  |
|----|------------------|--|
| 8  | Milipore Filter  | Satorius membrane filter<br>Gm bH, W. Germany. |
| 9  | Light Microscope | Olympus, Japan.                                |
| 10 | Micropipette     | Oxford, USA.                                   |
| 11 | pH Meter         | Hoeleze and Cheluis, KG,<br>Germany.           |
| 12 | Water Bath       | Memmert, Germany                               |

### 2.1.2 Chemical and Biological Material

Table (2): Chemical and Biological  
Materials Used

| Name of material  | Company             |
|---|---------------------|
| <b>A- Chemical Materials</b>  |                     |
| Na <sub>2</sub> HPO <sub>4</sub> , K <sub>2</sub> HPO <sub>4</sub> , KNO <sub>3</sub> , NaCl, MgSO <sub>4</sub> ,<br>HCL, CaCl <sub>2</sub> , KOH | Merk-<br>Darmstadt. |

|  |                           |
|--|---------------------------|
| <b>alpha-nephthol amine, esculine, Tetramethyl-p-paraphylene diamine dihydrochloride, Acetic acid, Amyl alcohol, Sulfanilic acid, Methyl red, Olic acid, Chloroform, Phenol red, peptone</b> | B.D.H                     |
| H <sub>2</sub> O <sub>2</sub> , Glucose, Sucrose, Trehalose, 99% alcohol.  | Fluka chemika-Switzerland |
| <b>B- Culture media</b>  |                           |
| Blood agar base, Brain heart infusion agar, Brain heart infusion broth, agar-agar, Muller-Hinton agar  | Mast.                     |
| Gelatin liquefaction medium, Pepton water medium, Urea agar medium, Nutrient agar media, Nutrient broth  | Oxiod                     |
| Tryptic soy agar, Tryptic soy broth, Meet extract  | Diffco-Michigan.          |

## 2.2 Patients and Methods

### 2.2.1 Patients

Three hundred samples are collected from patients suffering from acute or chronic pharyngitis who admitted ENT unit in Babylon City

(children and adults) from both sexes. The history of disease is also obtained from each patient according to the following formula:

Name, Age, Sex, Chief Complaint and Duration, History of present illness, Drug history and history of systemic disease.

### **۲.۲.۲ Collection of Specimens**

The specimens are generally collected from patients with pharyngitis. The swab should be used to collect as much exudates as possible from the tonsils and posterior pharyngeal wall. The swab should be rubbed with rotation over one tonsillar area, then the arch of the soft palate and uvula, the other tonsillar area, and finally the posterior pharyngeal wall. The swabs for culture should be placed in a tube containing normal saline to maintain the swab moist until it is taken to laboratory (Collee, *et.al.*, ۱۹۹۶).

The swabs are plated on a selective culture medium (Coman, *et.al.*, ۱۹۹۶). (۵% sheep or human blood agar) using tryptic soy agar base and containing ۳.۵% NaCl. The plates are incubated for ۴۸- ۷۲ hours in an aerobic condition (۵-۱۰% Co<sub>۲</sub>) at ۳۷°C.

This medium has been found to facilitate the isolation of *A.haemolyticum*.

### २.२.३ Reagents

#### १- Catalase reagent:-

It is prepared by adding ३ml of  $H_2O_2$  to १००ml distill water and stored in a dark container used to detect the catalase enzyme (Baron, *et.al.*, १९९०).

#### २- Oxidase reagent:-

This is soon prepared by dissolving ०.१g of tetra-p-paraphenylene diamine dihydrochloride in १०ml of distill water and stored in a dark container (Baron, *et.al.*, १९९०).

#### ३- Nitrate reduction reagent:-

This is prepared according to (Collee, *et.al.*, १९९६) .

**The First solution** is prepared by dissolving १g of sulfunilic acid in १००ml of ०M acetic acid.

**The Second solution** is prepared by dissolving ०g of alpha-naphthyl amine in १००ml of ०M acetic acid.

Equal volume of each solution is mixed to prepare the reagent.

#### ४-Kovac's reagent:-

This reagent has been prepared by dissolving १gm from p-Dimethyl amino benzaldehyde (DAMB) in १००ml of amyl alcohol; ०ml of concentrated HCL are gradually added to this mixture. This

solution is stored in a dark bottle, and gently shaken before use. It is used in the demonstration of indole production (MacFaddin, 2000).

#### **5-Phenol Red Reagent:-**

It has been prepared by dissolving 0.1g from phenol red stain in 300 ml of ethylalcohol (90%) then the volume is completed to 500 ml by distilled water. It is used to detect the acidity of the media ,which is produced by complete fermentation of carbohydrates (MacFaddin, 2000).

#### **6- Voges-Proskauer Reagent:-**

**A-** 0g of alph-nepthol is dissolved in 100 ml of 99% alcohol, and stored in a refrigerator in a brown glass bottle away from light.

**B-** 4g of KOH is dissolved in 100 ml of distilled water (Collee, *et.al.*, 1996).

#### **7- Methyl Red Reagent:-**

It has been prepared by dissolving 0.1g from methyl red stain in 300 ml of ethyl alcohol (90%) then the volume is completed to 500 ml by distilled water. It is used to detect the acidity of the medium,

which is produced by complete fermentation of carbohydrates (Collee, *et.al.*, 1996).

## 2.2.4 The preparation of media

### 1- Esculin Media:-

This media was made from preparation of nutrient agar with 1.5gm ferric citrate and 4gm esculin are added to it and volume was completed to 100ml; after that the media is poured into tubes and sterilized into autoclave, and then slant of media is formed (Baron, *et.al.*, 1990).

### 2- Lipolytic Media:-

The media contains the following ingredients;

- 1g of peptone.
- 20g of sodium chloride.
- 0.05 g of calcium chloride.
- 2 g agar.

All these are suspended in 100 ml of distilled water, containing 1.0ml of oleic acid and this media was used to detect lipase production (Collee, *et.al.*, 1996).

### 3- Nitrate Reduction Media:-

It has been prepared by dissolving a mixture of 0.5g of potassium nitrate ( $KNO_3$ ), 0g peptone in 100ml of distilled water. In water bath, the final volume is distributed into test tubes and autoclaved. It is used for the detection of the ability of bacteria to reduce nitrate into nitrite (Collee, *et.al.*, 1996).

#### 4 - Peptone Water Media:-

It has been prepared by dissolving 1g peptone in 1 liter of distilled water, of distributed into test tubes, and autoclaved. It is used for the demonstration of the bacterial ability to decompose the amino acid treptophan to indole (MacFaddin, 2000).

#### 5 - Gelatin Liquefaction Media:-

It has been prepared by adding 1% gelatin to nutrient broth. This medium is used for testing the ability of bacteria to gelatin liquefaction (Collee, *et.al.*, 1996).

#### 6 - Urea Agar Media:-

This medium has been prepared by adding 10ml of urea solution (sterilized by filtration 0.45 mm) into 100ml of urea agar base sterilized by autoclaving and cooling to  $50^{\circ}C$ , the pH is adjusted into 7.1 and the medium distributed into sterilized test tubes and allowed

to solidify in a slant form. It was used to test the ability of bacteria to produce enzyme urease (MacFaddin, 2000).

### **U-Sugar Fermentation Media:**

Medium is composed of:

#### **A. Basal medium:**

It is prepared by dissolving 10g pepton, 1g meat extract (Difco), 9g Sodium chloride (NaCl) and 0.01g phenol red (BDH) in one liter distilled water, then the pH is adjusted to 7.4. The Medium is distributed on test tubes, and durham tubes added to each test tube then sterilized by an autoclave (MacFaddin, 2000).

#### **B. Sugar solutions:**

Sugar solutions are prepared by dissolving 1g sugar in 100ml distilled water and sterilized by filtration, then 0.1ml sugar solution is added to each test tube (Item-1) containing 9ml from the basal medium. The medium was used for diagnose pathogenic bacteria that have the ability to ferment sugar (MacFaddin, 2000).

8- **M<sup>9</sup> media**:- ( Miniatis, *et.al.*, 1982)

1g of Na<sub>2</sub>HPO<sub>4</sub>, 3g of KH<sub>2</sub>PO<sub>4</sub>, 0.0g of NaCl, and 1g of NH<sub>4</sub>Cl, are dissolved in 90.0ml of D.W. with 2% agar, and then sterilized into autoclave. After cooling the mixture to 50.0 C, 2ml of 1m of MgSO<sub>4</sub>, 1.0 ml of 20% glucose and 0.1 ml of 1m of CaCl<sub>2</sub> (sterilized them separately by filtration) are added, then the volume is completed to 100.0 ml .

## 2.2.0 Biochemical Tests

### 1- Catalase Test:-

A small amount of bacterial growth on the medium at a 24 hour age is transferred by sterile wooden stick onto the surface of a clean, dry glass slide, and one drop of (3% H<sub>2</sub>O<sub>2</sub>) is added to it. The formation of gas bubbles indicates the positive results (Collee, *et.al.*, 1996).

### 2- Oxidase Test:-

A small portion of the colony to be tested is transferred by a sterile wooden stick to filter paper saturated with an indicator prepared soon. If the color around the smear turns rose to purple, the oxidase test is positive (Collee, *et.al.*, 1996).

### **Ƴ - Esculin Test:-**

The organism is grown in an esculin slant for Ƴ<sup>ε</sup>hr. at ƳƳ<sup>o</sup>C. The dark brown color indicates a positive result. The unchanging of the color is a negative result (Baron, *et.al.*, 1990).

### **ξ - Indole Test:-**

This test is performed by inoculating peptone water medium with bacterial growth, and incubated at ƳƳ<sup>o</sup>C for ξ^hr afterwards, 1.0ml of Kovacs reagent is added, and the tube was gently shaken; the formation of red- ring between the medium and reagents indicates a positive result (MacFaddin, 2000).

### **o - Voges-Proskauer Test:-**

The test is performed by using MR-VP broth. The inoculated media is incubated for Ƴ<sup>ε</sup>hr. at ƳƳ<sup>o</sup>C. Afterwards, 10 drops of 0% alpha-naphthol are added and followed by 10 drops 4.0% KOH. The mixture is shaken well and allowed to stand up to 10 minutes before calling a reaction negative. If positive, the culture turns red at the surface of the liquid, and the color spreads gradually through the

tube. The positive result indicates a partial analysis of glucose which produces (Acetyl-carbonyl) (Collee, *et.al.*, 1996).

#### 6- Methyl Red Test:-

This test is carried out by inoculating tubes containing MR-VP medium with bacterial growth. The tube is incubated at 37°C for (24-48) hr. and 5 drops of methyl red indicator are added. The appearance of red color after 10 minutes indicates a positive test (Collee, *et.al.*, 1996).

#### 7- Urease Test:-

This test is carried out by inoculating urea medium with bacterial growth and incubated at 37°C for 24h. The color change of medium into pink indicates a positive result (MacFaddin, 2000).

#### 8- Reverse CAMP Test:-

The CAMP inhibition test is achieved by streaking the presumed *A. haemolyticum* strain at right angle toward *Staphylococcus aureus* and incubation for 48hr. beta – hemolysis inhibition zone in the form of a triangle is observed as in the case of *A. haemolyticum* (Patrick, *et.al.*, 2003).

#### 9- Carbohydrate Fermentation Test:-

Carbohydrate fermentation medium is inoculated with bacterial culture and incubated at 37°C for 24-72 hr. The Color change of the

medium from red to yellow and gas formation in the Durham tube indicate a positive result (MacFaddin, 2000).

### **2.2.6 Isolation and identification of *A. haemolyticum***

*A. haemolyticum* is slow growing beta-hemolytic Gram positive rod. The hemolysis and morphology of colonies are affected by the media, atmosphere and incubation time used for isolation.

Tryptic soy agar produces the largest colony size and incubation in carbon dioxide for minimum of 48 hours yields the most discernible colonies (Cummings, et.al., 1993).

The characteristic pitting of the agar may be observed by pushing the colony aside. Rough and smooth colony types have been described. Colonies are circular, discoid, opaque and whitish.

Further identification characteristics include a negative catalase and positive reverse CAMP test.

### **2.2.7 Virulence Factors Tests**

#### **2.2.7.1 Hemolysin production:-**

Hemolysin production is shown on blood agar media. The results are obtained after the incubation of the non-cultured plates for 24

hr. at 37°C to exclude any contamination of blood, and then the organism is inoculated at this blood agar plates and incubated again for 48 hr. at 37°C. Any hemolysis presence should be detected around the colonies (Deboy, *et.al.*, 1980).

#### **2.2.7.2 Lipase production:-**

It is qualitatively prepared by incubating the isolates for 24-48 hours on lipolytic medium. Clearing of the medium around the colonies would indicate an isolate producing lipase (Chamberlain and Brueggemann, 1997).

#### **2.2.7.3 Protease production:-**

M<sup>9</sup> is supplemented with 2% agar used for the detection of protease enzymes. After sterilization in autoclave and cooling at 50°C, 0.20 gm/L glucose (sterilized by filtrations) is added, and then the media is supported by 1% Gelatin. After the inoculation of this media with bacterial strain and incubation for 48hr. at 37°C, 2 ml of Trichloroacetic acid (5%) is added to precipitate the protein. The positive result is read by observing a transparent area around the colony (Piret, *et.al.*, 1983).

#### **ॡ.ॡ.ॡ.ॡ Phospholipase D production:-**

Brain heart infusion broth is prepared with ॡ.ॡ% of glycerol. After sterilization in autoclave and cooling at ॡॡ°C, the organism is inoculated at this broth and incubated again for ॡ^hr. at ॡॡ°C.

The supernants fluids are then obtained by the filtrations of culture media containing *A.haemolyticum*.

Wells are made on Brain heart agar supplemented with ॡ% sheep blood and then filled with filtrates to show the production of PLD.

Streaking of *Staphylococcus aureus* isolates are done horizontally by using sterile swab on all the surface of the medium except the area of the wells for ॡ^hr. at ॡॡ°C.

The results show a beta-hemolysis inhibiting zone of *Staphylococcus aureus* around the wells.

#### **ॡ.ॡ.^ Effect of temperature on bacterial growth:-**

The isolated bacteria are re-inoculated on blood agar and then incubated at various temperature degrees to show their ability to grow at these degrees.

#### **ॡ.ॡ.9 Antibiotic Sensivity Test**

Antibiotic diffusion test (The Kirby-Baur susceptibility test) is used to show the effect of antibiotics on isolated bacteria.

1. It is performed by using a pure culture of previously identified bacterial organism.

The inoculums to be used in this test are prepared by adding growth from 10 isolated colonies grown on blood agar plate to 10 ml of broth. This culture is then incubated for 18 hr. to produce bacterial suspension of moderate turbidity.

*A sterile swab is used to obtain inoculums from the standardized culture. This inoculum is then streaked on tryptic soy agar plates supplemented with 10% human blood.*

2. The antibiotic discs are placed on the surface of the medium at evenly spaced intervals with flamed forceps or disc applicator.
3. Incubation for 18 hr. at 37°C, antibiotic inhibition zones are measured using caliper.

Zone size is measured to determine the susceptibility or resistance of organism to each antibiotic (MacFaddin, 2000).

Antibiotic disc supplied from Oxoid Company can be disc potency by mg / ml concentration as follows:

| <b>Antibiotics</b> | <b>Disc Potency</b> |
|--------------------|---------------------|
| Ery.               | ۱۵                  |
| Do.                | ۳۰                  |
| Ctx.               | ۳۰                  |
| Van.               | ۳۰                  |
| Cip.               | ۵                   |
| DA.                | ۵                   |
| Am.                | ۱۰                  |
| Pn.                | ۱۰                  |
| CN.                | ۱۰                  |
| Azm.               | ۱۵                  |
| Cl.                | ۳۰                  |
| Tet.               | ۳۰                  |

Ery: Erythromycin; Do: Doxycyclin; CL: cephalixin; Ctx: cephotaxime;  
 Van: Vancomycin; Cip: Ciproflaxine; DA: Clindamycin; Am: Ampicilin;  
 Pn: Penicillin; CN: Gentamycin;  
 Azm: Azithromycin; Tet: Tetracycline.

## Chapter Three

# Results and Discussion

### 3.1 Isolation and Characterization

This study deals with 300 throat swabs obtained from patients (male or female) suffering from pharyngitis. The patient had been admitted to ENT unite Surgical Teaching Hospital in Hilla over period of 8 month from October 2004 to May 2005.

All swabs have been subjected to culture on selective medium:

Sheep or human blood agar using tryptic soy agar base and containing 3.5% sodium chloride have been used to facilitate the isolation of *A.haemolyticum* and improve isolation of group A (*Streptococcus Pyogenes*) and group C and G beta-hemolytic *Streptococci*. commensal oropharyngeal flora such as viridance streptococci, *Neisseria* species, non haemolytic streptococci and beta- haemolytic streptococci not belonging to group A, B, C or G were significant inhibited (Watt, *et.al.*, 1991).

It was seen that out of the total swabs obtained from patients with pharyngitis, 100 samples gave positive culture for *A.haemolyticum* and *Streptococcus sp.* and 190 samples did negtive culture, however, the results of bacterial isolation (Table 3) show that only eight isolates (2.6%) of *A.haemolyticum* were isolated.

Three of them from female patients and the other five isolates from male patients. This result is identical to those obtained by (Karpathios, *et.al.*, 1992) who have reported a higher incidence of pharyngitis caused by *A.haemolyticum* in males compared with females. But Fell, *et.al.*, (1977) have reported a higher incidence in female than in male.

The results obtained in this study are identical with those obtained by Linder, (1997) who has succeeded to isolate *A. haemolyticum* at a rate reaching 2.0%.

Bank and Nyman, (1986) have also isolated *A.haemolyticum* from patients with pharyngitis at a rate of 3% with the highest numbers among 10 – 30 year old patients. Kuo, *et.al.* (1990) and Roman and Garcia, (2000) have also reported the isolation of this bacteria from patients with pharyngitis by a rate of 2.0% and 3% respectively, especially among adolescents.

In addition, Mackenzie, *et.al.* (1990) have isolated *A.haemolyticum* from patients with pharyngitis at a rate of 2.0% with the maximum occurrence in the 10 – 18 year-old age group.

Jurankova and Votava, (2001) and Dorbat, *et.al.* (1996) have isolated *A.haemolyticum* from patients with pharyngitis at a rate of (0.06%) and (0.43%) respectively. Arikan, *et.al.*, (1997) have also isolated *A.haemolyticum* from patients with pharyngitis at a rate of

0.3%. Furthermore, Carlson, *et.al.*, (1990) and Chen, *et.al.*, (2005) have isolated this bacteria by the rate of 1.4% and 0.2% respectively.

The frequency of *A.haemolyticum* in throat swabs investigated is 0.07% as compared with *Streptococcus pyogenes* found in 8.21% of cases (Coman, *et.al.*, 1996).

However, there are other types of bacteria than *A.haemolyticum* isolated in this study. All of these belong to the genus *streptococcus* sp.

It is known that oral cavity and most cases of pharyngitis may be caused by *streptococcus* sp. ,so, the isolation of *Streptococcus* in this study is probable and is worth mentioning.(Table 3).

**Table (3): Frequency of Positive Culture and Negative Culture on Selective Media**

| Patients<br>No. | POSITIVE CULTURE |                                    | NE<br>CU |
|-----------------|------------------|------------------------------------|----------|
|                 | A.haemolyticum   | <i>Streptococcus</i><br><i>sp.</i> |          |
| 300             | 8                | 97                                 |          |
| %               | 2.6%             | 32.3%                              |          |

Furthermore, the distribution of *A.haemolyticum* pharyngitis according to patient's ages has also been studied (Table 4).

Most infections of *A. haemolyticum* appear at a high rate of (70%) among ages ranging from (6 – 10) years old in both sexes and (20%) of the infection among the ages ranging from (20 – 40) years old. The results of this study are identical with those obtained by Arian, *et.al.* (1997) which deals with the prevalence of *A. haemolyticum* infections in the age between (6 – 22) years old. Kain, *et.al.*, (1991) have also observed that *A. haemolyticum* infections are a common cause of pharyngitis in the 10 – 30 year old age groups. However, pharyngitis caused by *A. haemolyticum* most commonly affects teenagers and young adults in the second and third decade of life (Carlson, *et.al.*, 1994).

**Table (4): Distribution of *A. haemolyticum* Infections among Age and Sex**

| Age     | Sex  |        | Number | %    |
|---------|------|--------|--------|------|
|         | Male | Female |        |      |
| 1 – 10  | 2    | 1      | 3      | 37.5 |
| 11 – 20 | 1    | 2      | 3      | 37.5 |
| 21 – 30 | 1    | 0      | 1      | 12.5 |
| 31 – 40 | 1    | 0      | 1      | 12.5 |
| > 40    | 0    | 0      | 0      | 0    |
| Total   | 5    | 3      | 8      | 100  |

Moreover, there are no isolates of *A. haemolyticum* found in the healthy controls. This result is correlated with those results obtained by Fell, *et.al.*, (1973) and David, *et.al.*, (1996) who have pointed that *A. haemolyticum* is not a part of the oral bacterial flora. On the other hand, Karpathios, *et.al.*, (1992) could not isolate *A. haemolyticum* from the throat flora of 308 symptomless children. But Banck and Nyman, (1986) have reported only one positive *A. haemolyticum* isolate among 100 healthy control subjects.

All the patients who have positive culture for *A. haemolyticum* have sore throat and fever, non productive cough and skin rash.

The clinical picture in patients with *A. haemolyticum* pharyngitis is similar to that reported earlier except that the typical rash is detected less often.

This result is identical with that obtained by Carlson, *et.al.*, (1990) who have indicated that the typical rash is less often (23%) than in some other reports, 86 – 88% (Karpathios, *et.al.*, 1992).

### **3.1.1 The Characteristics of *A. haemolyticum***

The definitive identification depends on the cultural characteristics and biochemical feature, the bacteria is gram – positive rod, catalase negative, facultatively anaerobic bacteria and

reverse CAMP test (narrowing of the haemolytic zone produced by Staphylococcal of beta-lysine).

It is nutritionally fastidious and grow on complex media enhanced by contain a blood. *A. haemolyticum* produces acid from glucose, lactose and maltose (Goyal, *et.al.*, 2000).

On blood agar containing human blood, it forms colonies like streptococci surrounded by wide zone of beta-hemolysis (Collee, *et.al.*, 1996). *A. haemolyticum* produces opaque, whitish and tiny colonies (Waagner, 1991) figure (1). Rough and smooth colonies have been described (Fell, *et.al.*, 1977). Most, but not all, strains produce a relatively beta-hemolysis.

The best medium for isolation and identification of *A. haemolyticum* is tryptic soy agar supplied with 0% human blood and 3.0% NaCl. *A. haemolyticum* is a slow growing and the growth is enhanced by the addition of 0 – 10% CO<sub>2</sub> (Cummings, *et.al.*, 1993).

The most important cultural and biochemical characteristics of *A. haemolyticum* are summarized in Table 0:

**Table 9: Diagnostic features of *A. haemolyticum***

| <b>Tests</b>         | <b>Results</b>                  |
|----------------------|---------------------------------|
| Growth on blood agar | White (smooth or rough biotype) |
| Shape of cell        | Rod ,pleomorphic                |
| Gram stain           | Positive                        |
| Catalase             | Negative                        |
| Indole               | Negative                        |
| Oxidase              | Negative                        |
| Nitrate reduction    | Negative                        |
| Gelatin hydrolysis   | Negative                        |
| Esculin              | Negative                        |
| Type of haemolysis   | Beta- haemolysis                |
| Urease               | Negative                        |
| VP                   | Negative                        |
| MR                   | Negative                        |
| Glucose              | Positive                        |
| Maltose              | Positive                        |
| Reverse CAMP         | Positive                        |



**Figure (١)**

***A. haemolyticum* appearance on blood agar**

### **٣.١.٢ Biotyping of *A. haemolyticum***

Colony morphology and beta hemolysis on sheep or human blood agar divide clinical *A. haemolyticum* isolates into smooth and rough

colony type (Carlson, *et.al.*, 1994). In this study, smooth and rough colony types are found on human blood agar after 48hr. of incubation.

The smooth and rough colony morphologies correlate with two biotype. Each smooth colony has glistening surface and an entire edge surrounded by a zone of moderate to strong beta- hemolysis.

On other hand, each rough colony has rough surface and irregular edge. Beta hemolysis is either absent or very weak, and dark discoloration around the colony is frequently noticed. It has been observed that 3(37.5%) isolates are of the smooth type and 5(62.5%) are of the rough type.

This result is similar to those reported by (Carlson, *et.al.*, 1994) who have established that the smooth type at a rate of (36%) and rough type at a rate of (64%) from pharyngitis infections. The biotype could be distinguished using biochemical test described by (Krech and Hollis, 1991). The smooth type could ferment sucrose and trehalose while the rough type is negative for both sugars (Table 6).

**Table 6: Properties of the two biotype of *A.haemolyticum***

| <b>Biotypes</b> | <b>No. of strain</b> | <b>Beta-hemolysis</b> | <b>Sucrose ferment</b> | <b>Trehalose ferment</b> |
|-----------------|----------------------|-----------------------|------------------------|--------------------------|
| Smooth          | 3                    | Moderate              | Positive               | Positive                 |

|       |   |                |          |          |
|-------|---|----------------|----------|----------|
|       |   | to strong      |          |          |
| Rough | o | Absent or weak | Negative | Negative |

The rough biotype is isolated from respiratory tract specimens and the smooth biotype comes mainly from wounds. Whether this difference is due to, for instance, different adherence properties remains to be established (Carlson, *et.al.*, 1994).

### 3.2.2 Reverse CAMP Test

The demonstration of phospholipase D (PLD) production by reverse CAMP test has been carried out (Zahorova and Kubella, 1960). This test is useful in the identification of *A.haemolyticum*.

The results showed that the strains are positive for reverse CAMP which have the capacity to block the hemolytic activity of the beta-lysine (phospholipase C) produced by *Staphylococcus aureus* on sheep blood agar.

Beta-lysin of *Staphylococcus aureus* possesses phospholipase C (sphingomyelinase) activity (hemolysis, lysis) against sheep erythrocytes and hydrolyzes the sphingomyelin provided by the erythrocytes (Maheswaran and Lindorfer, 1967).

Sphingomyelinase (sphingomyelin choline phosphohydrolase) from *Staphylococcus aureus* can attack the outer membrane of intact erythrocytes and produce water insoluble ceramide and phosphorylcholine (Zwaval, *et.al.*, 1973). PLD hydrolyzes sphingomyelins to N-acylsphingosylphosphates (Souckov and Soucek, 1974).

The basis of the test is that *Staphylococcus aureus* and Hemolysin act on the sphingomyelins in the cell membrane of sheep or human erythrocytes.

*A.haemolyticum* phospholipase D hydrolyzes these sphingomyelins thus protecting the blood cell from haemolysis (Soucekov and Soucek, 1972).

Bhat, *et.al.*, (1997) have shown that *A.haemolyticum* gives no hemolysis in CAMP test (reverse CAMP test positive) in contrast with CAMP tests which are used to produce CAMP factor which acts synergistically with *Staphylococcal* beta- hemolysin (beta-lysine) on sheep erythrocytes to produce alytic phenomenon (Darling, 1970). The CAMP factor is extracellular diffusible protein produced by group B streptococci, which lysis ruminant erythrocyte treated with beta-hemolysin (Jokipit and Jokipii, 1976).

### **3.3 Virulence Factors of *A.haemolyticum***

### 3.3.1 Hemolysin

Microorganism evolves a number of mechanisms for the acquisition of iron from their environments (Litwin and Calderwood, 1993). One of them is the production of hemolysin which acts to release iron complexes to intracellular heme and hemoglobin. Iron can increase disease risk by functioning as a readily available essential nutrient for invading microbial and neoplastic cell. To survive and replicate in hosts, microbial pathogens must acquire host iron (Weinberg, 1998).

To investigate the ability of *A. haemolyticum* to produce hemolysin on human blood agar, the results show that only three isolates are able to produce hemolysin and these isolates are smooth type (Table V). Whereas five isolates have no ability to produce this protein extracellularly and these isolates are rough types.

Carlson, *et.al.*, (1994) have shown that two biotypes of *A. haemolyticum*: one smooth type grows as a smooth, beta-hemolytic, whereas the other, the rough type, grows as rough colonies and is non hemolytic.

Furthermore, Hemolysin has also produced on tryptic soy agar supplemented with 3.0% NaCl and 0% human blood. Both colony size and zone of hemolysis were significantly greater on tryptic soy agar media. The CO<sub>2</sub> atmosphere was clearly superior for production of

larger hemolytic zones. Anaerobic incubation produce the smallest colonies and zone of hemolysis since production of noticeable hemolysis is critical for the recognition of *A.haemolyticum* colonies in the presence of other flora (Cumming, *et.al.*, 1993). Tryptic soy agar is the superior media and CO<sub>2</sub> was the superior atmosphere for beta-hemolysis.

### 3.3.2 Protease

In the ability of *A.haemolyticum* to produce extracellular protease by using M<sub>1</sub> media (supported by 0.2% glucose and 1% gelatin) is investigated and it is found that all isolates are not able to produce extracellular protease after 48 h. of incubation . There is no transparent area around the colony after the addition of 3ml (0%) of trichloro acetic acid (TCA) (Table 4).

This bacterium does not produce any secreted protease. It is definitely negative for gelatin and casein hydrolysis (Parija, *et.al.*, 2000), in contrast, *Arcanobacterium pyogenes* produce several protease which have the capacity to degrade host proteins releasing amino acid as nutrients and may degrade proteins such as IgA which are involved in host defense, and may also be involved in host tissue damage (Jost and Billington, 2000). These bacteria closely

resemble *Arcanobacterium haemolyticum* but *Arcanobacterium pyogenes* hydrolyse gelatin rapidly.

### ۳.۳.۳ Lipase

The ability of *A. haemolyticum* to produce lipase has been investigated. All isolates are able to produce lipase after ۴ hr. of incubation (table ۷). This result is identical with those obtained by (Coyle and Lipsky, ۱۹۹۰) who have pointed that this bacteria produce lipase.

The role of lipase in pharyngitis infections is not known. There is no previous study to indicate the role of this enzyme in *Arcanobacterium haemolyticum* infections in respiratory tract. However, the role of this enzyme may have a role in cutaneous infections as conflict mentions by (Al-khafaf, ۲۰۰۵).

The majority of microbial lipase has been reported to be large molecules of aggregates of protein-lipid or protein-protein (Pablo, *et.al.*, ۱۹۷۴). A structure of this type explains some of the conflicting data on the size and specify lipase as described by various groups isolated from different growth phases (Pablo, *et.al.*, ۱۹۷۴).

In cutaneous infections, this enzyme may help spread the organism in cutaneous and subcutaneous tissue through hydrolyzing

lipid on epithelial of surface of humans, enhanced colonization of the skin

(Koneman, *et.al.*, 1992).

The enzyme production can be arrested by various compounds such as tetracyclines which are effective against lipase production by interfering with protein synthesis by binding to bacterial ribosome (Andrews, 1990).


### 3.3.4 Phospholipase D

The ability of *A.haemolyticum* to produce phospholipase D (PLD) has been investigated. All isolates are able to produce PLD after 48 h. of incubation (table 4). The supernatant fluid of PLD inhibits the lytic action of beta- toxin produced by *Staphylococcus aureus* (Figure 2). Cuevas and Songer, (1993) have reported to produce soluble toxins including PLD and suggested a role of these enzymes in pathogenesis of infections by *A.haemolyticum*.

The PLD gene from *A.haemolyticum* has been cloned and shown to have a high degree of homology with that of *C.pseudotuberculosis* where it is thought to participate in vascular permeability and dissemination of the pathogen (Cuevas and Songer, 1993). PLD is an essential virulence determinant that contributes to the persistence and spread of the bacteria within the host (Mcnamara, *et.al.*, 1990).

PLD is the main virulence factor for this bacterium which catalyzes the hydrolysis of phosphatidylcholine (PC), the major membrane phospholipid, to form phosphatidic acid (PA) which may promote the colonization of the bacteria to the tissues and then induction of hemolytic activity and apoptosis (Mcnamara, *et.al.*, 1990).

These enzymes have broader substrate specificity, and their ability to catalyze transphosphatidyl transfer reactions has made them useful for synthesis of natural lipids (Mcdermott, *et.al.*, 2004). PLD is known to bring about tissue damage as elaborated by *A.haemolyticum* as well as the closely related bacterium, *Corynebacterium pseudotuberculosis* an important pathogen of sheep (Linder, 1997). The role of potentiated cytotoxicity caused by the combined activity of PLD and cooperative agents such as cholesterol data involving in phagocytosis (Linder and Bernheimer, 1982).



## Figure (۲)

### Phospholipase D Production by *A. Haemolyticum*

Table (۷): Detection of virulence factors on the *A. haemolyticum*

| Virulence factors | Isolation No. |              |              |               |              |              |               |               |
|-------------------|---------------|--------------|--------------|---------------|--------------|--------------|---------------|---------------|
|                   | ۱<br>(rough)  | ۲<br>(rough) | ۳<br>(rough) | ۴<br>(smooth) | ۵<br>(rough) | ۶<br>(rough) | ۷<br>(smooth) | ۸<br>(smooth) |
| <b>Hemolysin</b>  | -             | -            | -            | +             | -            | -            | +             | +             |
| <b>Protease</b>   | -             | -            | -            | -             | -            | -            | -             | -             |
| <b>Lipase</b>     | +             | +            | +            | +             | +            | +            | +             | +             |
| <b>PLD</b>        | +             | +            | +            | +             | +            | +            | +             | +             |

### PLD: phospholipase D

#### ۲.۴ Effect of Temperature on *A. haemolyticum* Growth

As shown in Table (۸) the results reveal that *A. haemolyticum* grows well at (۴-۴۰)°C and that the optimum growth of *A. haemolyticum* isolates at temperature ranging from ۳۵-۳۷°C under anaerobic conditions which resembles the temperature of the body.

The bacterial growth has been completely inhibited at a temperature of ۴۰°C. The results are identical to those recorded by

Waagner, (1991) who showed that the Optimum growth of *A. haemolyticum* occurs at 37°C, in either microaerphilic or anerobic conditions. The temperature can effect the bacterial enzymes through it is influence on the three- dimensional configuration of protein, thereby affecting the rates of enzymatic activities.

The optimal temperature of growth is 37°C but a culture can be obtained for other tempertures (in particular for tempertures ranging between 20 and 40°C (Euze'by, 1999).

**Table (^): Effect of Temperature on the Growth of *A. haemolyticum* Isolates**

| Temp.<br>°C | Iso. 1<br>(rough) | Iso. 2<br>(rough) | Iso. 3<br>(rough) | Iso. 4<br>(smooth) | Iso. 5<br>(rough) | Iso. 6<br>(rough) | Iso. 7<br>(smooth) | Iso. 8<br>(smooth) |
|-------------|-------------------|-------------------|-------------------|--------------------|-------------------|-------------------|--------------------|--------------------|
| 30 - 40     | +                 | +                 | +                 | +                  | +                 | +                 | +                  | +                  |
| > 40        | -                 | -                 | -                 | -                  | -                 | -                 | -                  | -                  |

### 3.9 Effect of some Antibiotics on *A. haemolyticum*

Some antibiotics are used to show their effect on *A. haemolyticum* isolates such as erythromycin, deoxycycline, cephalixin, cefotaxime, vancomycin, ciprofloxacin, clindamycin, ampicilin, pencilin, gentamicin, azithromycin and tetracycline .

It has been found that *A.haemolyticum* isolates are sensitive (100%) to erythromycin, penicillin and azithromycin and resistant (100%) to gentamycin whereas some isolates have shown resistance in lesser degree to vancomycin (62.5%), cefotaxime (0%), cephalixin, clindamycin and ampicilin (33%). The isolates are also resistant to doxycycline, ciproflaxine and tetracycline at a rate of (20%) (Table 9).

**Table 9: Effect of antibiotics on the Growth of *A .haemolyticum***

| Isolate No. | Ery. | Do | Cl. | Ctx. | Van. | Cip. | DA. | Am. | Pn. | CN. | Azm. | Tet. |
|-------------|------|----|-----|------|------|------|-----|-----|-----|-----|------|------|
| 1 rough     | -    | -  | +   | -    | +    | +    | -   | +   | -   | +   | -    | -    |
| 2 rough     | -    | -  | +   | +    | -    | -    | +   | -   | -   | +   | -    | -    |
| 3 rough     | -    | +  | -   | +    | -    | -    | -   | +   | -   | +   | -    | -    |
| 4 smooth    | -    | +  | +   | -    | +    | +    | +   | -   | -   | +   | -    | +    |
| 5 rough     | -    | -  | -   | -    | +    | -    | -   | -   | -   | +   | -    | -    |

|                     |   |    |      |    |      |    |      |      |   |     |   |    |
|---------------------|---|----|------|----|------|----|------|------|---|-----|---|----|
| γ rough             | - | -  | -    | +  | +    | -  | -    | -    | - | +   | - | -  |
| γ smooth            | - | -  | -    | +  | -    | -  | +    | -    | - | +   | - | +  |
| λ smooth            | - | -  | -    | -  | +    | -  | -    | +    | - | +   | - | -  |
| Rate of resistant % | 0 | 20 | 37.0 | 00 | 62.0 | 20 | 37.0 | 37.0 | 0 | 100 | 0 | 20 |

+: Resistant, -: Sensitive

There are only a few reports of the susceptibility of *A. haemolyticum* to antimicrobial agents and only the penicillin and erythromycin have been reported (Nyman, *et.al.*, 1990).

All the isolates have shown sensitivity to penicillin. This result is identical with those obtained by (Cambier, *et.al.*, 1992) and (Carlson, *et.al.*, 1994). However some reports, have mentioned that treatment failure with penicillin has been attributed to tolerance and to failure to penetrate the intracellular location of the pathogen (Linder, 1997).

The ability of *A. haemolyticum* to invade HEP-2 cells and survive intracellularly has been investigated. (Alos, *et.al.*, 1990) and (Skov, *et.al.*, 1998) have also reported that most isolates are considered to be tolerant to penicillin. On other hand, some isolates have shown resistance to ampicillin. Notario, *et.al.*, (2001) have observed that the isolates of *A. haemolyticum* are susceptible to ampicillin.

Furthermore, all the isolates have shown sensitivity to erythromycin and this antibiotic, as it is known is the drug of choice for *A. haemolyticum* treatment (Gaston and Zurowski, 1996).

Erythromycin is known as a macrolid antibiotic and is the first choice for patients with penicillin allergies a 10 day regimen is needed (Bisno, 2001).

Erythromycin, an antibiotic known to penetrate well intracellularly, efficiently kills these bacteria (Osterlund, 1990). This antibiotic inhibits bacterial growth, possibly by blocking dissociation of peptidyl-tRNA from ribosomes, arresting RNA-dependent protein synthesis (Miller, *et.al.*, 1986).

On the other hand, all the isolates have shown sensitivity to azithromycin. Another macrolide, azithromycin can be given as using daily dose and may be effective in five days. This antibiotic is bacteriostatic agent which inhibit the growth of microorganisms by binding to the 50S subunit of the prokaryotic ribosome, blocking protein synthesis at the peptidyltransferase step. This antibiotic is likely efficacious for *A. haemolyticum* (Donald and Middleton, 1996). But this antibiotic produces fewer gastrointestinal side effects than does erythromycin (Michael and Pichichero, 1998). Macrolids also exhibit excellent activities against *Arcanobacterium* and are an alternative to beta-lactam antibiotic for the treatment of infection,

since treatment failures due to beta-lactam antibiotic to act intracellular have been reported (Patrick, *et.al.*, २००३).

The results also show that only two isolates of *A.haemolyticum* are resistant to tetracycline. This result is similar to those obtained by (Carlson, *et.al.*, १९९०). The Two strains belong to smooth biotype and their resistance to this drug is most commonly mediated either by active efflux of tetracycline from the cell or by ribosomal protection from the action of tetracycline Chopra and Roberts, (२००१). Probably the presence of TetW gene is widespread determinant of tetracycline resistance in *Arcanobacterium* sp. (Billington, *et.al.*, २००२).

Tetracycline is bacteriostatic especially in large doses and it is short acting. In small doses oral antibiotics do not reduce the number of organisms but they affect their function. The antibiotics can also inhibit various enzyme activities such as lipase by interfering with protein synthesis combining with bacterial ribosome (Andrews, १९९०).

Tetracyclines are incompletely absorbed from the gastrointestinal tract, but their absorption is improved in the fasting state. Food-mediated interference with absorption is lower with doxycycline .The results also show that two isolates are resistant to doxycycline. These antibiotics long – acting and more readily absorbed; therefore; lower doses are required (Chopra and Roberts, २००१).

Five isolates of *A.haemolyticum* are found resistant to vancomycin. The high-level constitutive resistance seen in these isolates appears to be mediated by Van A genes (Power, *et.al.*, 1990). The isolates of *A.haemolyticum* have previously been shown to be resistant to vancomycin and to harbour the transferable vancomycin resistance gene Van A (French, *et.al.*, 1992).

Besides, the effect of clindamycin on *A. haemolyticum* isolates was studied and it has been found that three isolates are resistant to clindamycin; two strains belong to the smooth biotype. Clindamycin inhibits bacterial growth possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA- dependent protein synthesis to arrest (Tai and Daris, 1980). This result is similar to those obtained by (Carlson, *et.al.*, 1999).

Furthermore, all isolates of *A.haemolyticum* are resistant to gentamycin. This results contrasts with those obtained by Nyman, *et.al.*, (1990) who have observed that the isolates of *A.haemolyticum* are sensitive to gentamycin .

Aminoglycosides appear effective invitro, although occasional resistant strains have been encountered (Worthington, *et.al.*, 1980).

The results also show that only two isolates of *A.haemolyticum* are resistant to ciproflaxein. This antibiotic can inhibit bacterial DNA synthesis, an event that is followed by rapid bacterial cell death.

Carlson, *et.al.*, (1994) have reported that the isolates are sensitive to ciproflaxin.

The results also show that three isolates (20%) are resistant to cephalixin. Biswas, *et.al.*, (2003) have found that the isolates of *A.haemolyticum* are sensitive to cephalixin. This antibiotic is the first-generation and cephalosporin has broader spectrum agents for all sore throat which arrests bacterial growth by inhibiting bacterial cell wall synthesis. Cephalosporins are potent, and are very effective in eradicating the bacteria. The results also show that some isolates are resistant to cefotaxime. It is a synthetic, broad-spectrum cephalosporin antibiotic. The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis (Mary, *et.al.*, 2000).

Goyal, *et.al.*, (2000) have observed that *A.haemolyticum* are sensitive to cefotaxime.

However, there is no difference between smooth and rough biotype in response to antibiotic sensitivity test, except for some antibiotic such as clindamycin and tetracycline. The results show that some strains belonging to smooth biotype are resistant to these antibiotics. These differences are qualitative but not essential.

Briefly, *A.haemolyticum* has recently been accepted as an important human pathogen but has been reported infrequently as a cause of well – defined infections, probably because of failure to

correctly identify the pathogen in clinical specimens. The correct identification and antibiotic sensitivity testing of such isolates are essential for the proper management of infected individuals.

## Chapter Four

# *Conclusions and Recommendations*

### 4.1 Conclusions

1. *A. haemolyticum* could easily be isolated on selective media using sheep blood agar with tryptic soy agar base containing 3.0% sodium chloride.
2. The number of *A. haemolyticum* isolated from 300 patients suffering from pharyngitis (children and adults) from both sexes is eight isolates (2.6%).
3. Cultures for streptococcal pharyngitis will allow detection of *A. haemolyticum*: when this bacteria is searched for, blood agar plates must be incubated for full 24hr. and examined carefully for typical haemolytic colonies.

- ξ. A sufficient number of subcultures and Gram stains should be performed. Especially if haemolytic streptococci are not detected in patients suffering from pharyngitis.
- ο. The isolates are susceptible to penicilin, cephalosporins, macrolids, doxycyclin, clindamycin and vancomycin, but resistant to gentamycin.
- ϒ. Two strains of *A.haemolyticum* were isolated rough and smooth biotypes on the basis of colony morphology and biochemical tests.
  
- Υ. *A.haemolyticum* is revealed to posseses more than one virulence factor such as phospholipase D, lipase, hemolysin production.
- Λ. Reverse CAMP test has been used for the identification of this bacteria. This test is useful for demonstrating PLD production by *A.haemolticum*.

## ٤.٢ Recommendations

According to the results obtained in the present study, it is recommended that further investigation be made as follows:

١. Study the prevalence of *Arcanobacterium haemolyticum* in cases other than pharyngitis.
٢. Investigations of other species of *Arcanobacterium* to show their prevalence in Iraq.
٣. Study of molecular basis of *Arcanobacterium haemolyticum* isolates in various infections.
٤. Detection on other enzymes and proteins associated with the pathogenicity of these bacteria.

## **References**

- Alberto, B., ٢٠٠٣. Pharyngitis Exudative Causada due to *A.haemolyticum*. *Rev. Costarric. Cienc.* ٢٤(٣-٤): ١٣٧-١٤٦.
- Al- Khafaf, M. R., ٢٠٠٥. Isolation and Characterization of *Propionibacterium Acnes* from Patients with Acne Vulgaris. MSc. Thesis. College of Science. Babylon University.

- Alonso, J. L., P. Garcia- Martos and J. A. Gonzales, 2002. Infections by *A.haemolyticum*: an emerging pathogen. *An. Med. Internet.* 19(9): 473-6.
- Alos, J. I., C. Barros and J. L. Gomez- Garces. 1990. Endocarditis caused by *Arcanobacterium haemolyticum* *Eur. J. Clin. Microbial. Infect. Dis.* 14: 1080-1088.
- Andrews, S. 1990. Andrews's disease of the skin. *Clinical Dermatology. N. Eng. J. Med.* 294: 703-706.
- Arikan, S., S. Erguven and A. Gunalp. 1997. Isolation in vitro antimicrobial susceptibility and penicillin tolerance of *A. haemolyticum* in Turkish university hospital. *Zent. Ralbl. Bakterial.* 286(4): 487-93.
- Banck, G. and M. Nyman. 1986. Tonsillitis and rash associated with *Corynebacterium haemolyticum*. *J. Infect. Dis.* 104: 1037-1040.
- Barker, K.F., N.E. Renton, Y.C. Leep and D.H. Jameas. 1992. *Arcanobacterium haemolyticum* wound infection. *J. Infect.* 24: 214-210.
- Barksdale, W.L., C.S. Cummins and H. Harris. 1907. The mutation of *Corynebacterium pyogens* to *Corynebacterium haemolyticum*. *J. Gen. Microbial.* 16: 749-708.

Baron, E.J., L.R. Peterson and S.M. Finegold. 1990. Bailey and Scott's diagnostic microbiology 10th Ed. The C.V. Mosby Company, Toronto. Canada.

Bernheimer, A.W., B.J. Campbell and L.J. Forrester. 1980. Comparative toxinology of *Loxosceles reclusa* and *Corynebacterium pseudotuberculosis*. *Science*. 228: 090-1.

Bhat, C., B.N. Hemashettar and C.S. Patil. 1997. *Arcanobacterium haemolyticum* in chronic wound infections. *Indian. J. Med. Microbiol.* 10(1): 41-42.

Billington, S.S., J.G. Songer and B.H. Jost. 2002. Widespread distribution of a Tet W determinant among tetracycline resistant isolates of the animal pathogen *Arcanobacterium pyogenes*. *Antimicrob. Agents. Chemother.* 46: 1281-1287.

Billah, M.M. and J.E. Anthes. 1990. The regulation and cellular function of phosphatidylcholine hydrolysis. *Biochem. J.* 269: 281-291.

Bisno, A.L. 1990. *Streptococcus pyogenes*. In: principles and practice of infectious disease. 4th edition. G.L. Mandell, J.E. Bennett, R. Dolin, eds. Churchill Living stone, N.Y.P. 1786-2047.

Bisno, A.L. 2001. Acute pharyngitis. *New Engl. J. Med.* 344(3): 200-211.

- Biswas, D., P. Gupta, R. Prasad and M. Arya. २००३. A case of chronic osteomyelitis due to *Arcanobacterium haemolyticum*. *Ind. J. Med. Microbiol.* २१: २०९-१०.
- Blazevic, D.J., and G.M. Edever १९७०. Principles of Biochemical Tests in Diagnostic Microbiology. New York. John Wiley and Sons. ३७-४०.
- Bradshaw, C.D., K.M. Ella, C. Qi, H.M. Sansbury, A.E. Wiseartjersona and K.E. Meier. १९९६. Effects of Phorbol ester on Phospholipase D and Mitogen-Activated Protein Kinase Activities in T. Lymphocyte cell lines. *Immunol. Lett.* ०३: ६९-७६.
- Brown, J., R. Farnsworth, L.W. Wannamaker and D.W. Johnson. १९७४. CAMP factor of group Streptococci production assay and neutralization by sera from immunized rabbits and experimentally infected cows. *Infect. Immun.* ९(२): ३७७-३८३.
- Byers, H.L., K.A. Homer, and D. Beighton. १९९७. Sialic acid utilisation by viridance Streptococci. *Adv. Exp. Med. Biol.* ४१८: ७१३-७१६.
- Cambier, M., M. Janssens and G. Wanters. १९९२. Isolation of *A. haemolyticum* from patients with pharyngitis in Belgium. *Act. Clin. Belg.* ४७: ३०३-३०७.
- Carlson, P., O.V. Renkonen, and S. Kontiainen. १९९४. *Arcanobacterium haemolyticum* and Streptococcal pharyngitis. *Scand. J. Infect. Dis.* २६: २८३-२८७.

- Carlson, P., S. Kontiainen, O.V. Renkonen. 1994. Antimicrobial susceptibility of *A. haemolyticum*. *Antimicrob. Agents. Chemther.* 38: 142-143.
- Carlson, P., K. Lounatmaa and S. Kontiainen. 1994. Biotypes of *A. haemolyticum*. *J. Clin. Microbiol.* 32: 1604-7.
- Carlson, P., S. Kontiainen, O.V. Renkonen, A. Sivonen and R. Visakorpi. 1990. *A. haemolyticum* streptococcal pharyngitis in army conscripts. *Scand.J. Infect. Dis.* 22(1): 17-8.
- Carlson, P., S. Korpela, M. Walder and M. Nyman. 1999. Antimicrobial susceptibility and biotypes of *A. haemolyticum* blood Isolates *Eur. J. Clin. Microbiol. Infect. Dis.* 18(12): 910-7.
- Chamberlain, N.R. and Bruggemann, S.A. (1997). Characterization and expression of fatty acid modifying enzyme produced by *Staphylococcus epidermidis*. *J. Med. Microbiol.* 46: 693-97.
- Chandrasekar, P.H. and J.A. Molinari. 1987. *Corynebacterium haemolyticum* bacteremia with fatal neurological complication in an intravenous drug addict. *Am. J. Med.* 82: 638-640.
- Chen, Y., R. Colodner, B. Chazan and R. Raz. 2000. Pharyngotonsillitis due to *Arcanobacterium haemolyticum* in Northern Israel. *IMAJ.* 7: 241-242.

- Childs, W.C., and R.J. Gibbons. 1990. Selective modulation of bacterial attachment to oral epithelial cells by enzyme activities associated with poor oral hygiene. *J. Periodontal. Res.* 25: 172-178.
- Chopra, L., and M. Roberts. 2001. Tetracycline antibiotics: mode of action, application, molecular biology, and epidemiology of bacterial resistance. *Microbiol. Mol. Biol. Rev.* 65: 232-260.
- Christie, R., N. Atkins and E. Munch-Peterson. 1944. A note on alytic phenomenon shown by group B Streptococci. *Aust. J. Exp. Biol. Med. Sci.* 22: 197-200.
- Clarridge, J.E. 1989. The recognition and significance of *Arcanobacterium haemolyticum*. *Clin. Microbiol. News* 11: 41-45.
- Cockcroft, S. 2001. Signalling roles of mammalian phospholipase D1 and D2. *Cell. Mol. Life. Sci.* 58: 1674-1687.
- Collee, J., A.G. Fraser, B.P. Marmiam and S.A. Simmon. 1996. Practical medical microbiology. 14th ed. The churchill livingston. Inc. USA.
- Collins, M.D., D. Jones, R. M. Kroppenstedt and K.H. Schleifer. 1982. Chemical studies as a guide to the classification of *Corynebacterium pyuogenes* and *Corynebacterium haemolyticum*. *J. Gen. Microbiol.* 128: 330-341.

Collins, M. D., D. Jones and G.M. Schofield. 1982. Reclassification of "*Corynebacterium haemolyticum*" in the genus *Arcanobacterium* gen. nov. as *Arcanobacterium haemolyticum* nom. rev., comb. nov. *J. Gen Microbiol.* 128:1279-81.

Coman, G., C. Panzaru and C. Dahorea. 1996. The isolation of *A.haemolyticum* from the pharyngeal exudate of children. *Bacterial Virusol Parazitol Epidemiol.* 41(3-4): 141-4

Coyle, M.B. and B.A. Lipsky. 1990. Coryneform bacteria in infectious disease: clinical and laboratory aspects. *Clin. Microbial. Rev.* 3: 227-246.

Cross, M., S. Roberts, A.J. Ridley, M. Hodgkin, A. Stewart, L. Claesson-welsh and M. J. O. Wakelam. 1996. Stimulation of actin stress fiber formation mediated by activation of phospholipase D . *Curr. Biol.* 6:588-597.

Cuevas, W.A., and J.G. Songer. 1993. *A.haemolyticum* Phospholipase D is genetically and functionally similar to *Corynebacterium pseudotuberculosis* phospholipase D. *Infect. Immun.* 61: 4310-6.

Cummings, L.A., A.M. Larson, S.E. Gavin, J.S. Fine and M.B. Coyle. 1993. Effect of media, atmosphere and incubation time on

colonial morphology of *Arcanobacterium haemolyticum*. *J. Clin. Microbiol.* 31: 3223-3226.

Darling, C.L. 1970. Standardization and evaluation of the CAMP reaction for the prompt. Presumptive identification of *Streptococcus agalactiae*. In clinical material. *J. Clin. Microbio.* 1(2): 171-174.

David, A., M.D. Gaston, M. Susan and M.D. Zurowski. 1996. *Arcanobacterium haemolyticum* pharyngitis and exanthema. *Arch. Dermatol.* 132: 61-64.

Deboy, J., K. Wachsumth and B. Davis. 1980. Hemolysin activity in enterotoxigenic and non- enterotoxigenic strains of *E.coli* . *J. Clin. Microbiol.* 12: 193-198.

Dennis, E.A. 1983. Phospholipase. In: Boyer PD, ed. The enzymes. New York: Academic Press. 307-303.

Dieleman, L.A., S. Demarie, R.S. Monton, J.L. Bloom, W.G. Peters, A.J. Bos, 1989. Paraverebral abscess due to nondiphtheria coryneform bacteria as a complication of ingrown toenails *Infection.* 17: 26-7.

Donald, B., and M.D. Middleton. 1996. Pharyngitis. *Clinics in office practice.* 23:4.

- Dorbat, O., S. Erscoin and M. Burtea. 1996. Pharyngitis produced by *A. haemolyticum*. *Bacteriol. Virusol. Parazitol. Epidemiol.* 4(3-4): 130-41.
- Eady, E.A., E. Ingham and C.E. Walters. 1993. Modulation of condonal levels of interleukin-1 in acne patients treated with tetracyclines. *J. In. Vest. Dermatol.* 10.1: 86-91.
- Euzeb'y, J.P. *Arcanobacterium. pyogenes*. 1999. Veterinary dictionary of bacteriology. (cited by intrnet).
- Exton, J.H. 1994. Phosphatidylcholine break down and signal transduction. *Biochim. Biophys. Acta.* 1212: 26-42.
- Fell, H.W., J. Nagington, G.R. Naylor and R.J. Olds. 1973. Infections of man with *Corynebacterium haemolyticum*. *J. Med. Microbiol.* 1: pvii.
- Fell, H.W. K., J. Nagington and G.R. E. Naylor. 1977. *Corynebacterium haemolyticum* infections in Cambridgeshire. *J. Hyg.* 79: 269-274.
- Fiucci, G.M., Y. Czarny, Y. Lavie, D. Zhao, B. Borse, J.K. Blusztajn and M. Liscovitch. 2000. Changes of PLD isoform activity and expression in multidrug-resistant human cancer cells. *Int. J. Cancer.* 89: 882-8.

- Ford, J.G., R.P. Yeatts and L.B. Givner. 1990. Orbital cellulitis, subperiosteal abscess, sinusitis and septicemia caused by *Arcanobacterium haemolyticum*. *Am. J. Patho. Mol.* 120: 261-2.
- Frankel, P., M. Ramos, S. Flom, S. Bychenok, T. Joseph, E. Korkhoff, U.R. Rapp, L.A. Feig and D.A. Foster. 1999. Raf and Rhoddependent activation of PLD in v-Raf-transformed cells. *Biochem. Biophys. Res. Commun.* 255: 502-7.
- French, G., Y. Abdulla, R. Heathcock, S. Doston and J.Cameron. 1992. Vancomycin resistance in south london. *Lancet.* 339: 818-819.
- Funke, G., A. Vongraevenitz, J.E. Clarridge and K.A. Bernard. 1997. Clinical microbiology of coryneform bacteria. *Clin. Microbiol. Rev.* 10: 120.
- Galen, J.E., J. Ketiey, A. Fasano, S.H. Richardson, S.S. Wasserman, and J.B. Kaper. 1992. Role of *vibrio cholerae* neuraminidase in the function of Cholera toxin. *Infect. Immun.* 60: 406-410.
- Gaston, D.A. 1996. *Arcanobacterium haemolyticum* pharyngitis. Three cases reports and literature review. *Archives of Dermatology.* 132(1): 61-4.

Gaston, D.A. and S.M. Zurowski. 1996. *Arcanobacterium haemolyticum* pharyngitis and exanthema. *Arch. Dermatol.* 132: 61-64.

Gottschalk, A. 1960. Correlation between composition, structure, shape and function of salivary mucoprotein. *Nature.* 186: 949-951.

Goyal, R., N.P. Singh and M. Mathur. 2000. Septic arthritis due to *Arcanobacterium haemolyticum*. *Indian Journal of medical microbiology.* 23(1): 63-65.

Green, S.L., and K.S. Lapeter. 1981. Pseudodiphtheritic membranous pharyngitis caused by *Corynebacterium haemolyticum*. *J. Am. A.* 2330-1.

Gubash, S.M. 1978. Synergistic hemolysis phenomenon shown by an alpha-toxin-producing *Closteridium perfringens* and streptococcal grouping. *J. Clin. Microbial.* 1(5): 480-488.

Hammond, S.M., Y.M. Altshuller, T. Sung, S.A. Rudge, A.J. Morris and M.A. Froman. 1990. Human ADPribosylation factor-activated phosphatidylcholine specific phospholipase D defines a new and highly conserved gene family. *J. Biol. Chem.* 270: 79640-79643.

Hanahan, D.J. and I.L. Chaikoff. 1947. Phospholipase D. *J. Biol. Chem.* 168: 233-240.

Harper, H.A., V.W. Rodwell and P.A. Mayes. 1977. Review of physiological chemistry. 16<sup>th</sup> ed Los Altos. CA Lange Medical Publications. 131-133.

Harrow, B. and A. Mazur. 1966. Textbook of biochemistry, 9<sup>th</sup> ed. Philadelphia: W.B. Saunders, 310-316.

Hoosen, A.A., M.N. Rasool and L. Roux. 1990. Posttraumatic ankle joint infection with *Arcanobacterium haemolyticum*: a case report. *J. Infect. Dis.* 162:780-781.

Jokipit, A.M. M., L. Jokipii. 1976. Presumptive identification and antibiotic susceptibility of group B *Streptococci*. *J. Clin. Pathol.* 29(8): 736-739.

Jost, B.H., J.G. Songer and S.J. Billington. 2001. Cloning, expression and characterization of a neuraminidase gene from *Arcanobacterium pyogenes*. *Infection and immunity.* 69(7): 2230-2237.

Jost, B.H., and S.J. Billington. 2000. *Arcanobacterium pyogenes*: molecular pathogenesis of an animal opportunistic. *Antonie.Van. Leeuwenhoek.* 77: 87-102.

Juronkova, J. and M. Votava. 2001. Detection of *Arcanobacterium haemolyticum* in primo culture with reverse CAMP test. *Epidemol. Microbiol. Immunol.* 90(2): 71-3.

- Kain, K.C., M.A. Noble, R.L. Barteluk and R.H. Tubbesing. 1991. *A. haemolyticum* infection: confused with scarlet fever and diphtheria. *J. Emerg. Med.* 9(1-2): 33-5.
- Kanfer, J.N., D.G. McCartney, I.N. Singh and L. Freysz. 1996. Acidic phospholipids inhibit the phospholipase D activity of rat brain neuronal nuclei. *FEBS Lett.* 383: 6-8.
- Karpathios, T., S. Darkonaki, A. Zervondaki, G. Coupari, A. Fretzayas, J. Kremastinos and T. Thomcidis. 1992. *Arcanobacterium haemolyticum* in children with presumed Streptococcal pharyngotonsillitis or scarlet fever. *J. Pediatr.* 121: 730-737.
- Katkar, V.J., S.N. Shrikhande, A. Deshpande and N.S. Tankhiwale. 2005. Respiratory tract infection due to *A. haemolyticum*. *Indian. J. Pathol. Microbiol.* 48(2): 217-218.
- Kim, K.O., K.H. Lee, Y.H. Kim, S.K. Park and J.S. Han. 2003. Anti-apoptotic role of phospholipase D isozymes in the glutamate-induced cell death. *Exp. Mol. Med.* 35: 38-40.
- Koneman, E.W., S.D. Allen, W.M. Janda. . 1992. Color atlas and textbook of diagnostic microbiology. 4<sup>th</sup> ed, Philadelphia. J.B. Lippincott. 573- 585.
- Kovatch, A.L., K.E. Schuit and R.H. Michaels. 1983. *Corynebacterium hemolyticum* peritonsillar abscess mimicking diphtheria. *JAMA.* 249: 1707-1708.

Krech, T. and D.G. Hollis. 1991. Corynebacterium and related organism. In Balows, A., W. J. Hausler, K.L. Hermann, H.D. Isenberg and H.J. Shadomy (ed): Manual of Clinical Microbiology. American Society for Microbiology Washington D.C., P: 277-286.

Kuo, L.C., L.A. Jackson, L.A. Campbell and J.T. Grayston. 1990. *Chlamydia pneumoniae*. Rev: 1(4): 401-61.

Kurioka, S. and M. Matsuda. 1970. Phospholipase C assay using p-nitrophenylphosphorylcholine together with sorbitol and its application to studying the metal and detergent requirement of the enzyme. *Anal. Biochem.* 70: 281-289.

Kusner, D.J., C.F. Hall and L.S. Schlesinger. 1996. Activation of phospholipase D is tightly coupled to the phagocytosis of *Mycobacterium tuberculosis*. *J. Exp. Med.* 184: 580-590.

Linder, R. 1997. *Rhodococcus equi* and *Arcanobacterium haemolyticum*: two coryneform bacteria increasing recognized as agents of human infections. *Emerg. Infect. Dis.* 3: 140-53.

Linder, R. and A.W. Bernheimer. 1982. Cytotoxicity of *Rhodococcus equi* related to generation of cholesterol in macrophage and erythrocyte membranes. *Vet. Microbiol.* 213: 390-404.

Liscovitch, M. and A. Amsterdam. 1989. Onadotropin- releasin hormonec activates phospolipase D in ovarian granulosa cells. Possible role in signal transduction. *J. Biol. Chem.* 264: 11762- 11767.

Litwin, C.M. and S.B. Calderwood. 1993. Role of iron in regulation of virulence genes. *Clin. Microbial. Rev.* 6: 137-149.

Lonon, M.K., D.E. Wood and D.C. Straus. 1988. Production of lipase by clinical isolates of *Pseudomonas cepacia*. *J. Clin. Microbial.* 26(5): 979-984.

Lounatmaa, K., Haapasalo, E. Kerosuo and H. Jousimies-Somer. 1993. S – layers found on clinical isolates. In Beveridge, T.J., S.F. Koval: Advances in bacterial paracrystalline surface layer. *Plenum. Pres.* 33-43.

MacFaddin, J.F. 2000. Biochemical tests for the identification of medical bacteria 3<sup>rd</sup> ed. The Williams and Wilkins- Batimer USA.

Mackenzie, A., L. A. Fulte, F.T.H. Chan, J. King, A. Allen, N. Macdondaldand F. Diaz- Mitoma. 1990. Incidence and pathogenicity of *Arcanobacterium haemolyticum* during 2 years study in Ottawa. *Clin. Infect. Dis.* 21:177-81.

- Maclean, P.D., A.A. Liebow and A.A. Rosenberg. 1986. A hemolytic *Corynebacterium* resembling *Corynebacterium ovis* and *Corynebacterium pyogenes* in Man. *J. Infect. Dis.* 5: 69-90.
- Maheswaran, S.K. and R.K. Lindorfer. 1967. Staphylococcal alpha-hemolysin. Phospholipase C activity of purified alpha-hemolysin. *J. Bacteriol.* 94(5): 1313-1319.
- Mandell, G.L., J.E. Bennetts and R. Dolin. 2000. Principles and practice of infectious diseases. 6th ed. Churchill livingstone.
- Mary, J., A. Richard and C. Pamela. 2000. Lippincott's. Illustrated Reviews: Pharmacology. 5th ed. Lippincott William and Wilkins, London, New York.
- Mcdermott, M., M.J. O. Wakelam and A.J. Morris. 2004. Phospholipase D<sub>1</sub>, 2. *Biochem. Cell. Biol.* 82: 220-203.
- Mcnamara, P. J., W. A. Cuevas and J. G. Songer. 1990. Toxic phospholipase D of *Corynebacterium pseudotuberculosis*, *C. ulcerans* and *A. haemolyticum*: Cloning and sequence homology. *Gene.* 106: 113-118.
- Mebta, C. L. 2003. *Arcanobacterium haemolyticum*. *Am. ACAD. Dermatol.* 48: 2.

- Meier, K.E., T.C. Gibbs, S.M. Ella. 1999. Expression of phospholipase D isoforms in mammalian cells. *Biochim. Biophys. Acta.* 1439: 199-213.
- Michael, E., and M.D. Pichichero. 1998. Group A beta-hemolytic Streptococcal infections. *American Academy of Pediatrics.* 19: 9.
- Miller, R.A., F. Brancatocato and K.K. Holmes. 1986. *Corynebacterium haemolyticum* as a cause of pharyngitis and scarlatiform rash in young adults. *Ann. Intern. Med.* 105: 867-872.
- Minarik, T.J. Sufliarsky, J. Trupl and V. Krcmery. 1997. *Arcanobacterium haemolyticum* invasive infections including meningitis in cancer patients. *J. Infect.* 34: 91.
- Miniatis, T., E. Fritsch and J. Sambrock. 1982. Molecular cloning: a laboratory manual. Cold spring Harbour laboratory. New York.
- Muller, H.E. 1973. Neuraminidase and acylneuraminat-pyruvat-lyase bei *Corynebacterium haemolyticum* and *Corynebacterium pyogenes*. *Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. [A]*. 225: 59-60.
- Notario, R.D., N.G. Bor, T.M. Gambande and N. Dottori. 2001. *A. haemolyticum* sinusitis. *Rev. fac. Cien. Med. Univ. Nac. Cordoba.* 58 (1): 100-7.

- Nyman, M., G. Banck, and M. Thore. 1990. Penicillin tolerance in *Arcanobacterium haemolyticum*. *J. Infect. Dis.* 161: 261-265.
- Orihuela, C.J., G. Gao, K.P. Francis, J. Yu, and E.I. Tuomanen. 2004. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. *J. Infect. Dis.* 190: 1661-1669.
- Osterlund, A. 1990. Are penicillin treatment failures in *Arcanobacterium haemolyticum* pharyngotonsillitis by intracellularly residing bacteria? *Scand. J. Infect. Dis.* 22(2): 131-4.
- Pablo, G., A. Iiummetis, S. Bradbey and J.E. Futton. 1974. Characteristics of the extracellular lipase from *Corynebacterium acnes* and *Staphylococcus epidermidis*. *J. Invest. Dermatol.* 63: 231-238.
- Pai, J. K., E.A. Frank, C. Blood and M. Chu. 1994. Novel ketoepoxides block phospholipase D activation and tumor cell invasion. *Anticancer. Drug. Des.* 4: 363-372.
- Panzara, C., and T. Taranu. 2001. Venous ulcer infection caused by *Arcanobacterium haemolyticum*. *Roum. Arch. Microbiol. Immunol.* 60(4): 323-7.
- Parija, S., V. Kaliaperumal, S. Kumar and S. Sujatha. 2000. *A. haemolyticum* associated with pyothorax. *BMC Infectious disease* 0: 68.

Park, J. B., J.H. Kim, Y. Kim, S.H. Ha, J. Yoo, G. Du, M.A. Frohman, P. Suh and S.H. Ryn. 2001. Cardiac phospholipase D $\gamma$  localizes to sarcolemmal membranes and is inhibited by alpha-actinin in an adp-ribosylation factor-reversible manner. *J. Biol. Chem.* 276: 21290-21301.

Patrick R. Murray, E.J. Baron, M.A. P Faller, J.H. Jorgensen and R.H. Yolken. 2003. *Clinical microbiology*. 8<sup>th</sup> ed. Vol.

Piret, J., J. Millet and A. Demain. 1983. Production of intracellular protease, during sporulation of *Bacillus brevis*. *Eur. J. Appl. Microbiol. Biotechnol.* 17: 227-230.

Power, E.G.,Y.H. Abdulla, H.G. Talsania, W. Spice, S. Aathithan and G.L. French. 1990. Van A genes in vancomycin-resistant clinical isolates of *Oerskovia turbata* and *Arcanobacterium (Corynebacterium haemolyticum)*. 36(4): 090-6.6.

Provost, J.J., J. Fudge, S. Israelit, A.R. Siddiqi and J.H. Exton. 1996. Tissue-specific distribution of phospholipase D in rat: evidence for distinct RhoA and ADP-ribosylation factor $\gamma$ -regulated isoenzymes. *Biochem. J.* 311: 280-291.

Ramires deMolina, A., A. Rodriguez-Genzalez and J.C. Lacal. 2001. Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase. *Int. J. Oncol.* 19: 0-17.

- Ramos, P.C., G. Foster and M.D. Collins. 1997. Phylogenetic analysis of the genus *Actinomyces* based on 16S rRNA gene sequences: description of *A.phocae* sp. nov., *A.berardiae* comb.nov., and *A.pyogenes* comb. nov. *Int. J. Syst. Bacteriol.* 47: 46-53.
- Reich, R., M. Blumental, and M. Liscovitch. 1995. Role of phospholipase D in laminin- induced production of gelatinases in metastatic cells. *Clin. Exp. Metastasis* .13: 134-140.
- Reinholdt, J., M. Tomana, S.B. Mortensen and M. Kilian. 1990. Molecular aspects of immunoglobulin A, degradation by oral Streptococci. *Infect. Immun.*58: 1186-1194.
- Richardson, A., and P.J. Smith. 1968. Herd fertility and *Corynebacterium haemolyticum* in bovine semen. *Vet. Rec.* 83: 106-107.
- Ritter, E., A. Kaschner, C. Becker, E. Becker-Boost, C.H. Wirsing Vonknig and H. Finger. 1993. Isolation of *Arcanobacterium haemolyticum* from an infected foot wound . *Eur. J. Clin. Microbiol.Infect. Dis.* 12: 473-474.
- Roggentin, P., B. Rothe, J.B. Kaper, J. Galen, L. Lawrisuk, E.C. Vimr and R. Schauer. 1989. Conserved sequences in bacterial and viral sialidases. *Glycoconjugate. J.* 6: 349-353.

- Roman, J.C., and Y.P. Garcia. 2000. *Arcanobacterium haemolyticum*. *Rev. Chil. Infect.* 22(4): 300.
- Ropert, R.J. 1969. Isolation of *Corynebacterium haemolyticum* from a case of ovine pneumonia. *Vet Rec.* 84: 490.
- Shalita, A.R., V. Wheatly and P.E. Poch. 1982. Inhibition of parareatic lipase by tetracycline. *J. Invest. Dermatol.* 54: 413-410.
- Siddhanta, A., J.M. Backer and D. Shields. 2000. Inhibition of phosphatidic acid synthesis alters the structure of the golgi apparatus and inhibits secretion in endocrine cells. *J. Biol. Chem.* 275: 12023- 12031.
- Skov, R. L., A.K. Sanden, V.H. Danchell, K. Robertsen and T. Ejlersen. 1998. Systemic and deep seated infections caused by *Arcanobacterium haemolyticum*. *Eur. J. Clin. Microbial. Infect. Dis.* 17: 578-82.
- Snow, V., C. Mottur-pillon, R.J. Cooper. 2001. Principles of appropriate antibiotic use for acute Pharyngitis in adults. *Ann. Intern. Med.* 134(6): 506-8.
- Soucek, A., A. Souckova, M. Mara and F. Patocka. 1962. Observation on the biological properties of a typical haemolytic Corunebacteria isolated from man as comperad with *Corynebacterium haemolyticum*, *Corynebacterium pyogenes*

*bovis* and *Corynebacterium ovis*. П. *In vitro* investigating. *J. Hyg. Epidemiol. Microbiol. Immunol.* 6: 13-23.

Soucek, A. and A. Souckova. 1964. Immunological demonstration of antigen produced by *Corynebacterium pyogen* variet as *hominis*. Ш *J. Hyg. Epidemiol. Microbia* . 8: 192-206.

Soucek, A., and A. Souckova. 1966. Phospholipase A in *corynebacterium pyogenes hominis*. *J. Hyg. Epidemiol. Microbial. Immunol.* 10: 120-126.

Soucek, A., C. Michalec and A. Souckova. 1971. Identification and characterization of new enzyme of the group phospholipase D isolated from *Corynebacterium ovis*. *Biochem. Biophys. Acta.* 227: 116-28.

Soucek, A. and A. Soucekova. 1974. Toxicity of bacterial sphingomylenase D. *J. Hyg. Epidemiol. Microbial. Immunol.* 18: 71-79.

Souckov, A., A. Soucek. 1972. Inhibition of the hemolytic action of alph and beta lysins of *Staphylococcus pyogenes* by *Corynebacterium haemolyticum*, *Corynebacterium ovis*, *Corynebacterium ulceranes*. *Toxicon.* 10: 001-009.

Spear, B.S., N.B. Shoemaker and A.A. Salyers. 1992. Bacterial resistance to tetracycline: mechanisms, transfer and clinical significance. *Clin. Microbiol. Rev.* 5: 387-399.

Stacey, A., and A. Bradlow. 1999. *Arcanobacterium haemolyticum* and *Mycoplasma pneumoniae* co-infection. *J. Infect.* 38: 41-2.

Suchard, S.J., T. Nakamura, A. Abe, J.A. Shayman and L.A. Boxer. 1994. Phospholipase D-mediated diradylglycerol formation coincides with  $H_2O_2$  and lactoferrin release in adherent human neutrophils. *J. Biol. Chem.* 269: 8063-8068.

Tai, P.C., and B.D. Daris. 1980. The actions of antibiotics on the ribosome. In: Greenwood, D., F., O'Grady, eds. The scientific basis of antimicrobial chemotherapy. Cambridge. 14-68.

Taylor, G. 1996. Sialidases: structures, biological significance and therapeutic potential. *Curr. Opin. Struct. Biol.* 6: 830-837.

Uchida, N., S. Okamura and H. Kuwamo. 1999. Phospholipase D activity in human gastric carcinoma. *Anticancer. Res.* 19: 671-6.

VanDijk, M.C. M., F. Postom, H. Hilkmann, K. Jalin, W.J. Vanblitterswijk and W.H. Moolenaar. 1998. Exogenous PLD

generates lysophosphatidic acid and activates Ras, Rho and  $Ca^{+y}$  signalling pathways. *Curr. Biol.* 1: 386-392.

Waagner, D.C. 1991. *Arcanobacterium haemolyticum*: biology of the organism and disease in man. *Pediatr. Infect. Dis. J.* 10: 933-39.

Waite, K.A., R. Wallin, D. Qualliotine-mann and L.C. Mcphail. 1998. Phosphatidic acid- mediated phosphorylation of the NADPH oxidase component p $\epsilon$  $\gamma$ - phox. Evidence that phosphatidic acid may activate a novel protein kinase. *J. Biol. Chem.* 272: 10069-10078.

Waller, K.S., J. Johnson and B.P. Wood. 1991. Cavitory pneumonia due to *Arcanobacterium haemolyticum*. *Am. J. Dis. Child.* 140: 209-210.

Watt, L.L., C.A. Fleming, D.S. Hodge and C. Krishan. 1991. Selecitve medium for isolation of *A.haemolyticum* and *Streptococcus pyogenes*. *Eur. J. Clin. Microbiol. Infect. Dis.* 10: 443-446.

Waxman, D.J., and J.L. Strominger. 1983. Penicillin- binding proteins and the mechanism of action of beta-Lactam antibiotics. *Annu. Rev. Biochem.* 52: 820-869.

Webster, G.F. 1982. Acne vulgaris. State of the science. *Arch. Dermatol.* 130: 1101-1102.

- Weinberg, E.D. 1998. Pathological ecological implication of microbial acquisition of host iron. *Review in Medical Microbiology*. 9: 171-8.
- Welsh, C.S., C. Yeh and J.M. Phang. 1994. Increased phospholipase D activity in multidrug resistant breast cancer cells. *Biochem. Biophys. Res. Commun.* 202: 211-217.
- White, C.B., and W.S. Foshee. 2000. Upper respiratory tract infections in adolescents. *Adolesc. Med.* 11: 220-29.
- Wickremesinghe, R.S.B. 1981. *Corynebacterium haemolyticum* infections in Srilanka. *J. Hyg.* 87: 271-276.
- Willet, H.P. 1976. *Staphylococcus*. In: Joklik, W. K., H. P. Willett, eds. Zinsser's microbiology, 16<sup>th</sup> ed. New York, Appleton- Croft. 412.
- Worthington, M.G., B.D. Daly and F.E. Smith. 1980. *Corynebacterium haemolyticum* endocarditis on a native valve south. *Med. J.* 78(10): 1261-2.
- Zahorova, L. and V. Kubelka. 1960. A reverse CAMP diagnostic test with *Corynebacterium pyogenes varietas hominis*. *Folia. Microbial.* (5): 07-09.
- Zhao, Y., H. Ehara, Y. Akao, M. Shamato, Y. Nakagawa, Y. Banno, T. Deguchi, N. Ohishi, K. Yaki, Y. Nozawa. 2000. Increased

activity and intracellular expression of PLD in human renal cancer. *Biochem. Biophys. Res. Commun.* 278: 140-3.

Zwavall, R.F.A., B. Reeiefsen and C.M. Collen .1973. Localization of red cell membrane constituents. *Biochim. Biophys. Acta.* 300:109-112.